217 results on '"Arrojo M"'
Search Results
52. La regla contra las perpetuidades en el derecho inglés
- Author
-
Fernández-Arrojo, M. (María)
- Subjects
- Materias Investigacion::Derecho, derecho inglés, common law, derecho de la propiedad
- Abstract
La regla contra las perpetuidades es un limite a la facultad de disponer del propietario que establece un equilibrio entre los intereses jurídicos relativos a la disposición de miembros de generaciones sucesivas. La tesis tiene tres capítulos: El primero analiza diversos conceptos del derecho ingles necesarios para entender la descripción posterior de la institución estudiada. Todos ellos pertenecen al área jurídica de la propiedad. El segundo capitulo contiene el análisis global del principio contra la perpetuidad; El estudio comienza con los derechos contingentes, objeto del mismo. Después se analiza el medio con que cuenta el derecho ingles para crear derechos limitados y sucesivos en los bienes, o instrumento de la vinculación. En tercer lugar se realiza un estudio histórico desde dos perspectivas: La jurídica y la socio-económica. Finalmente, se describe la operatividad del principio, tal y como vige actualmente. El tercer capitulo describe las dos vertientes de la polémica a que ha dado lugar esta regla en las ultimas décadas. Por un lado, una discusión sobre la función actual del principio y, por otro, los diversos conceptos defendidos de las "vidas medidoras del periodo de perpetuidad" en la doctrina, así como un estudio de dicho concepto a través de la jurisprudencia del Common Law.
- Published
- 2018
53. Psychiatric presentation of Hashimoto's encephalopathy.
- Author
-
Arrojo M, Perez-Rodriguez MM, Mota M, Moreira R, Azevedo A, Oliveira A, Abreu P, Marques P, Silva A, Pereira JG, Palha AP, and Baca-Garcia E
- Published
- 2007
- Full Text
- View/download PDF
54. Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study
- Author
-
B. Pignon, H. Peyre, A. Ayrolles, J. B. Kirkbride, S. Jamain, A. Ferchiou, J. R. Richard, G. Baudin, S. Tosato, H. Jongsma, L. de Haan, I. Tarricone, M. Bernardo, E. Velthorst, M. Braca, C. Arango, M. Arrojo, J. Bobes, C. M. Del-Ben, M. Di Forti, C. Gayer-Anderson, P. B. Jones, C. La Cascia, A. Lasalvia, P. R. Menezes, D. Quattrone, J. Sanjuán, J. P. Selten, A. Tortelli, P. M. Llorca, J. van Os, B. P. F. Rutten, R. M. Murray, C. Morgan, M. Leboyer, A. Szöke, F. Schürhoff, Pignon B., Peyre H., Ayrolles A., Kirkbride J.B., Jamain S., Ferchiou A., Richard J.R., Baudin G., Tosato S., Jongsma H., de Haan L., Tarricone I., Bernardo M., Velthorst E., Braca M., Arango C., Arrojo M., Bobes J., Del-Ben C.M., Di Forti M., Gayer-Anderson C., Jones P.B., La Cascia C., Lasalvia A., Menezes P.R., Quattrone D., Sanjuan J., Selten J.P., Tortelli A., Llorca P.M., van Os J., Rutten B.P.F., Murray R.M., Morgan C., Leboyer M., Szoke A., Schurhoff F., Pignon, B [0000-0003-0526-3136], Ayrolles, A [0000-0002-3202-0781], Kirkbride, JB [0000-0003-3401-0824], Tosato, S [0000-0002-9665-7538], Lasalvia, A [0000-0001-9963-6081], Morgan, C [0000-0002-1386-2369], Apollo - University of Cambridge Repository, Pignon, B, Peyre, H, Ayrolles, A, Kirkbride, J B, Jamain, S, Ferchiou, A, Richard, J R, Baudin, G, Tosato, S, Jongsma, H, de Haan, L, Tarricone, I, Bernardo, M, Velthorst, E, Braca, M, Arango, C, Arrojo, M, Bobes, J, Del-Ben, C M, Di Forti, M, Gayer-Anderson, C, Jones, P B, La Cascia, C, Lasalvia, A, Menezes, P R, Quattrone, D, Sanjuán, J, Selten, J P, Tortelli, A, Llorca, P M, van Os, J, Rutten, B P F, Murray, R M, Morgan, C, Leboyer, M, Szöke, A, Schürhoff, F, Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), MUMC+: VPK Flexteam IC (9), MUMC+: MA Psychiatrie (3), and RS: MHeNs - R3 - Neuroscience
- Subjects
Schizophrenia/genetics ,Environmental effects on human beings ,Risk factors in diseases ,Epidemiology ,Psicosi ,psychosi ,Pathological psychology ,Genes × environment interaction ,Risk Factors ,Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat ,psychosocial stressors ,Humans ,psychosis ,Psychotic Disorders/genetics ,Settore MED/25 - Psichiatria ,Influència del medi ambient en l'home ,Genètica de la conducta ,Factors de risc en les malalties ,Genes × environment interactions ,Public Health, Environmental and Occupational Health ,Psychoses ,polygenic risk score for schizophrenia ,Psicopatologia ,Psychiatry and Mental health ,Psychotic Disorders ,Behavior genetics ,Schizophrenia ,Esquizofrènia ,Gene-Environment Interaction - Abstract
the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) and FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...), Pignon B, Peyre H, Ayrolles A, Kirkbride JB, Jamain S, Ferchiou A, Richard JR, Baudin G, Tosato S, Jongsma H, de Haan L, Tarricone I, Bernardo M, Velthorst E, Braca M, Arango C, Arrojo M, Bobes J, Del-Ben CM, Di Forti M, Gayer-Anderson C, Jones PB, La Cascia C, Lasalvia A, Menezes PR, Quattrone D, Sanjuán J, Selten JP, Tortelli A, Llorca PM, van Os J, Rutten BPF, Murray RM, Morgan C, Leboyer M, Szöke A, Schürhoff F
- Published
- 2022
- Full Text
- View/download PDF
55. The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings from the Multinational EU-GEI Study
- Author
-
Andrea Tortelli, Peter B. Jones, Jim van Os, Caterina La Cascia, Bart P. F. Rutten, Eva Velthorst, Baptiste Pignon, Celso Arango, Sarah Tosato, Lieuwe de Haan, Julio Sanjuán, Marion Leboyer, James B. Kirkbride, Antonio Lasalvia, Diego Quattrone, Cristina Marta Del-Ben, Andrei Szöke, Grégoire Baudin, Charlotte Gayer-Anderson, Pierre-Michel Llorca, Paulo Rossi Menezes, Robin M. Murray, Julio Bobes, Hannah E Jongsma, Miguel Bernardo, Mohamed Lajnef, Jean-Paul Selten, Hugo Peyre, Jean-Romain Richard, Franck Schürhoff, Craig Morgan, Marta Di Forti, Ilaria Tarricone, Mauro Braca, Manuel Arrojo, Aziz Ferchiou, Pignon, B., Lajnef, M., Kirkbride, J.B., Peyre, H., Ferchiou, A., Richard, J.-R., Baudin, G., Tosato, S., Jongsma, H., De Haan, L., Tarricone, I., Bernardo, M., Velthorst, E., Braca, M., Arango, C., Arrojo, M., Bobes, J., Del-Ben, C.M., Di Forti, M., Gayer-Anderson, C., Jones, P.B., La Cascia, C., Lasalvia, A., Menezes, P.R., Quattrone, D., Sanjuán, J., Selten, J.-P., Tortelli, A., Llorca, P.-M., Van Os, J., Rutten, B.P.F., Murray, R.M., Morgan, C., Leboyer, M., Szöke, A., Schürhoff, F., Pôle de Psychiatrie [Hôpital Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital H. Mondor - A. Chenevier, Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Pignon B., Lajnef M., Kirkbride J.B., Peyre H., Ferchiou A., Richard J.-R., Baudin G., Tosato S., Jongsma H., De Haan L., Tarricone I., Bernardo M., Velthorst E., Braca M., Arango C., Arrojo M., Bobes J., Del-Ben C.M., Di Forti M., Gayer-Anderson C., Jones P.B., La Cascia C., Lasalvia A., Menezes P.R., Quattrone D., Sanjuan J., Selten J.-P., Tortelli A., Llorca P.-M., Van Os J., Rutten B.P.F., Murray R.M., Morgan C., Leboyer M., Szoke A., Schurhoff F., Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: MA Psychiatrie (3), MUMC+: Hersen en Zenuw Centrum (3), and RS: MHeNs - R3 - Neuroscience
- Subjects
Male ,stressful life events ,Schizotypy ,positive subclinical symptom ,Ethnic group ,Social Environment ,subclinical psychosis ,positive subclinical symptoms ,0302 clinical medicine ,Adverse Childhood Experiences ,Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat ,SINTOMAS PSÍQUICOS ,subclinical psychosi ,10. No inequality ,COMMUNITY ASSESSMENT ,Subclinical infection ,GENERAL-POPULATION ,psychotic symptom ,Depression ,Confounding ,Social Discrimination ,depressive subclinical symptom ,stressful life event ,ETHNIC-GROUPS ,3. Good health ,Psychiatry and Mental health ,NEIGHBORHOOD CHARACTERISTICS ,ADULT PSYCHIATRIC-DISORDERS ,psychotic symptoms ,Adverse Childhood Experience ,Female ,psychosocial stress ,Psychology ,Psychosocial ,Human ,Clinical psychology ,negative subclinical symptom ,psychosocial stre ,Adult ,Psychosis ,Sibling ,LIFE EVENTS ,schizotypy ,Psychotic Disorder ,03 medical and health sciences ,Community Assessment of Psychic Experiences (CAPE) ,THREATENING EXPERIENCES ,medicine ,Humans ,European Union ,Settore MED/25 - Psichiatria ,childhood trauma ,Siblings ,Stressor ,medicine.disease ,PERCEIVED DISCRIMINATION ,negative subclinical symptoms ,030227 psychiatry ,PSYCHOMETRIC PROPERTIES ,Psychotic Disorders ,[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,dis crimination ,social capital ,depressive subclinical symptoms ,Stress, Psychological ,030217 neurology & neurosurgery ,Regular Articles ,discrimination - Abstract
The influence of psychosocial stressors on psychosis risk has usually been studied in isolation and after the onset of the disorder, potentially ignoring important confounding relationships or the fact that some stressors that may be the consequence of the disorder rather than preexisting. The study of subclinical psychosis could help to address some of these issues. In this study, we investigated whether there was (i) an association between dimensions of subclinical psychosis and several psychosocial stressors including: childhood trauma, self-reported discrimination experiences, low social capital, and stressful life experiences, and (ii) any evidence of environment-environment (ExE) interactions between these factors. Data were drawn from the EUGEI study, in which healthy controls (N = 1497) and siblings of subjects with a psychotic disorder (N = 265) were included in six countries. The association between psychosocial stressors and subclinical psychosis dimensions (positive, negative and depressive dimension as measured by the Community Assessment of Psychic Experiences (CAPE) scale) and possible ExE interactions were assessed using linear regression models. After adjusting for sex, age, ethnicity, country, and control/sibling status, childhood trauma (beta for positive dimension: 0.13, negative: 0.49, depressive: 0.26) and stressful life events (positive: 0.08, negative: 0.16, depressive: 0.17) were associated with the three dimensions. Lower social capital was associated with the negative and depression dimensions (negative: 0.26, depressive: 0.13), and self-reported discrimination experiences with the positive dimension (0.06). Our findings are in favor of independent, cumulative and non-specific influences of social adversities in subclinical psychosis in non-clinical populations, without arguments for E * E interactions. © The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
- Published
- 2021
- Full Text
- View/download PDF
56. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations
- Author
-
Rosana Shuhama, Gonzalo López, Viviana Storbini, Tolga Binbay, Ma Soledad Olmeda, Maria Calem, Marina Mihaljevic, Christos Pantelis, Halis Ulaş, Eva Velthorst, Jeroen Decoster, J. Malte Bumb, Ruud van Winkel, E. Cem Atbasoglu, Wolfgang Viechtbauer, Mirella Ruggeri, Erich Studerus, Daniele La Barbera, Domenico Berardi, Anita Riecher-Rössler, Stefan Borgwardt, Elsje van der Ven, Charlotte Rapp, Desiree Hilboll, Mark van der Gaag, Chiara Bonetto, Marie-Odile Krebs, Silvia Tenan, Monika Schlögelhofer, Robin M. Murray, Caterina La Cascia, Philip McGuire, Simona A. Stilo, Desmond Campbell, Fabienne Harrisberger, Teresa Sánchez, Catherine Derom, Franck Schürhoff, Philippe Delespaul, Jose Luis Santos, Emilio Sánchez, Stephan Ruhrmann, Luigi Rocco Chiri, Sabrina Cruz, Handan Noyan, Dominika Julkowski, Celso Arango, Merete Nordentoft, Stacey S. Cherny, Anne-Marie Galliot, Daniella van Dam, María Pouso, Asier Urruela Mora, G. Paul Amminger, Enrique García Bernardo, Ahmet Ayer, Tijana Mirjanic, Andrei Szöke, Anna Walter, Antonio Lasalvia, Isla Humphreys, Flora Frijda, Lieuwe de Haan, Neus Barrantes-Vidal, Nigel Williams, Burçin Cihan, Matthew J. Kempton, Ceren Akdeniz, Tamar Kraan, Andrea Tortelli, Barnaby Nelson, Marta Di Forti, Angelo Fioritti, Pedro Cuadrado, Eylem Sahin Cankurtaran, Emanuel Schwarz, Andreas Meyer-Lindenberg, Ilaria Tarricone, Laura Ferraro, Dan Rujescu, Anne-Marie Tronche, Laura Roldan, Bibiana Cabrera, Alp Üçok, Craig Morgan, Julio Sanjuán, Mauro Braca, Julio Bobes, Eric Y.H. Chen, Michael Conlon O'Donovan, Peter Holmans, Harald N. Aschauer, Sarah Ittig, Covadonga Martínez, Iris Lasser, Emiliano González, Aitziber Emaldi Cirión, Rachele Sartorio, F. Seminerio, Rodrigo A. Bressan, Ulrich Reininghaus, Elisa Brietzke, François Bourque, G Tripoli, Inez Myin-Germeys, Aziz Ferchiou, Gemma Modinos, Grégoire Baudin, Fabienne Soguel-Dit-Piquard, Cristina Marta Del-Ben, Gabriele Sachs, Elçin Akturan, Manuel Arrojo, Thomas R. Kwapil, Alice Mulè, Eva Mª Díaz Mesa, Federico Chierzi, Köksal Alptekin, Floor J. van der Meer, Pak C. Sham, Jim van Os, Adanna Onyejiaka, Mara Parellada, Bart P. F. Rutten, Jeanne Vilain, Michael John Owen, Sarah Tosato, Haldan Soygür, A.M. Marinaro, Stefania Tognin, Evert Thiery, Cathrin Rohleder, Mary Cannon, Miaoxin Li, F. Markus Leweke, Marc De Hert, Marta Rapado, Maria Gabriella Minenna, Pierre-Michel Llorca, Alexander Richards, Stéphane Jamain, Elles Messchaert, Nadja P. Maric, Semra Ulusoy, Elisa Ira, Peter G. Jones, Paulo Rossi Menezes, Patrick D. McGorry, Bernadette Winklbaur, Stephanie Beards, Nadine Burger, Güvem Gümüş-Akay, Marion Leboyer, James B. Kirkbride, Sinan Guloksuz, Ary Gadelha, E. Bulzacka, Carlos M. Romeo-Casabona, Gülşah Karadayı, Jean-Paul Selten, José Juan Rodríguez Solano, Kathryn Hubbard, Estela Jiménez, Thomas Charpeaud, Nikos C. Stefanis, Lucia Sideli, Miguel Bernardo, Jean-Romain Richard, Ivonne Donegani, Marco Seri, Lucia Valmaggia, Julia Paruch, Catherine van Zelst, Meram Can Saka, Heike Tost, Renata Smieskova, Thomas Marcacci, Nicholas John Craddock, Berna Binnur Akdede, Joachim Klosterkötter, Richard Bruggeman, Charlotte Gayer-Anderson, Sanja Andric, Elena Bonora, Angel Carracedo, Hasan Karadağ, Paula Cristobal, ANS - Amsterdam Neuroscience, Adult Psychiatry, Graduate School, Perceptual and Cognitive Neuroscience (PCN), Maastricht Univ, Kings Coll London, Mondriaan Mental Hlth Trust, Univ Groningen, Cardiff Univ, Cent Inst Mental Hlth, Dokuz Eylul Univ, Istanbul Univ, Ankara Univ, Yale Univ, Middle E Tech Univ, Diskapi YB Res & Training Hosp, Turkish Federat Schizophrenia Assoc, Ataturk Training & Res Hosp, Manisa Mental Hlth Hosp, Univ Complutense, Univ Barcelona, Univ Valencia, Univ Oviedo, Univ Santiago de Compostela, Hosp Virgen de la Luz, Hosp Univ Infanta Leonor Hosp Virgen Torre, Hosp Clin Univ, Hosp Psiquiatr Conxo, Univ Amsterdam, Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Parnassia Psychiat Inst, Rivierduinen Psychiat Inst, Grp Hosp Mondor, Hop Henri Mondor, Univ Paris Est, Fdn Fondamental, CMP B CHU, Univ Auvergne, EPS Maison Blanche, UPC KU Leuven, UPC, Katholieke Univ Leuven, Assoc Sci Res Multiple Births, Univ Ghent, Univ Athens, Med Univ Vienna, Psychiat Univ Clin Basel, Univ Cologne, Univ Hong Kong, Univ Basque Country, Univ Zaragoza, Univ Cambridge, UCL, Royal Coll Surgeons Ireland, Univ Munich, Univ Bologna, Local Hlth Trust, Univ Palermo, P Giaccone Gen Hosp, Univ Melbourne, Universidade de São Paulo (USP), Univ Verona, Copenhagen Univ Hosp, Univ Paris 05, Univ Autonoma Barcelona, St Pere Claver Fundacio Sanitaria, Univ N Carolina, CIBERSAM, Universidade Federal de São Paulo (UNIFESP), Univ Belgrade, van Os J, Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C, Bruggeman R, Reininghaus U, Morgan C, Murray RM, Di Forti M, McGuire P, Valmaggia LR, Kempton MJ, Gayer-Anderson C, Hubbard K, Beards S, Stilo SA, Onyejiaka A, Bourque F, Modinos G, Tognin S, Calem M, O'Donovan MC, Owen MJ, Holmans P, Williams N, Craddock N, Richards A, Humphreys I, Meyer-Lindenberg A, Leweke FM, Tost H, Akdeniz C, Rohleder C, Bumb JM, Schwarz E, Alptekin K, Üçok A, Saka MC, Atbaşoğlu EC, Gülöksüz S, Gumus-Akay G, Cihan B, Karadağ H, Soygür H, Cankurtaran EŞ, Ulusoy S, Akdede B, Binbay T, Ayer A, Noyan H, Karadayı G, Akturan E, Ulaş H, Arango C, Parellada M, Bernardo M, Sanjuán J, Bobes J, Arrojo M, Santos JL, Cuadrado P, Rodríguez Solano JJ, Carracedo A, García Bernardo E, Roldán L, López G, Cabrera B, Cruz S, Díaz Mesa EM, Pouso M, Jiménez E, Sánchez T, Rapado M, González E, Martínez C, Sánchez E, Olmeda MS, de Haan L, Velthorst E, van der Gaag M, Selten JP, van Dam D, van der Ven E, van der Meer F, Messchaert E, Kraan T, Burger N, Leboyer M, Szoke A, Schürhoff F, Llorca PM, Jamain S, Tortelli A, Frijda F, Vilain J, Galliot AM, Baudin G, Ferchiou A, Richard JR, Bulzacka E, Charpeaud T, Tronche AM, De Hert M, van Winkel R, Decoster J, Derom C, Thiery E, Stefanis NC, Sachs G, Aschauer H, Lasser I, Winklbaur B, Schlögelhofer M, Riecher-Rössler A, Borgwardt S, Walter A, Harrisberger F, Smieskova R, Rapp C, Ittig S, Soguel-dit-Piquard F, Studerus E, Klosterkötter J, Ruhrmann S, Paruch J, Julkowski D, Hilboll D, Sham PC, Cherny SS, Chen EY, Campbell DD, Li M, Romeo-Casabona CM, Emaldi Cirión A, Urruela Mora A, Jones P, Kirkbride J, Cannon M, Rujescu D, Tarricone I, Berardi D, Bonora E, Seri M, Marcacci T, Chiri L, Chierzi F, Storbini V, Braca M, Minenna MG, Donegani I, Fioritti A, La Barbera D, La Cascia CE, Mulè A, Sideli L, Sartorio R, Ferraro L, Tripoli G, Seminerio F, Marinaro AM, McGorry P, Nelson B, Amminger GP, Pantelis C, Menezes PR, Del-Ben CM, Gallo Tenan SH, Shuhama R, Ruggeri M, Tosato S, Lasalvia A, Bonetto C, Ira E, Nordentoft M, Krebs MO, Barrantes-Vidal N, Cristóbal P, Kwapil TR, Brietzke E, Bressan RA, Gadelha A, Maric NP, Andric S, Mihaljevic M, Mirjanic T, Clinical Psychology, EMGO+ - Mental Health, Van Os, J., Rutten, B., Myin Germeys, I., Delespaul, P., Viechtbauer, W., Van Zelst, C., Bruggeman, R., Reininghaus, U., Morgan, C., Murray, R., Di Forti, M., Mcguire, P., Valmaggia, L., Kempton, M., Gayer Anderson, C., Hubbard, K., Beards, S., Stilo, S., Onyejiaka, A., Bourque, F., Modinos, G., Tognin, S., Calem, M., O'Donovan, M., Owen, M., Holmans, P., Williams, N., Craddock, N., Richards, A., Humphreys, I., Meyer Lindenberg, A., Leweke, F., Tost, H., Akdeniz, C., Rohleder, C., Bumb, J., Schwarz, E., Alptekin, K., Üçok, A., Saka, M., Atbagoǧlu, E., Gülöksüz, S., Gumus Akay, G., Cihan, B., Karadaǧ, H., Soygür, H., Cankurtaran, E., Ulusoy, S., Akdede, B., Binbay, T., Ayer, A., Noyan, H., Karadayi, G., Akturan, E., Ulaş, H., Arango, C., Parellada, M., Bernardo, M., Sanjuán, J., Bobes, J., Arrojo, M., Santos, J., Cuadrado, P., Solano, J., Carracedo, A., Bernardo, E., Roldán, L., López, G., Cabrera, B., Cruz, S., Mesa, E., Pouso, M., Jiménez, E., Sánchez, T., Rapado, M., González, E., Martínez, C., Sánchez, E., Olmeda, M., De Haan, L., Velthorst, E., Van Der Gaag, M., Selten, J., Van Dam, D., Van Der Ven, E., Van Der Meer, F., Messchaert, E., Kraan, T., Burger, N., Leboyer, M., Szoke, A., Schürhoff, F., Llorca, P., Jamain, S., Tortelli, A., Frijda, F., Vilain, J., Galliot, A., Baudin, G., Ferchiou, A., Richard, J., Bulzacka, E., Charpeaud, T., Tronche, A., De Hert, M., Van Winkel, R., Decoster, J., Derom, C., Thiery, E., Stefanis, N., Sachs, G., Aschauer, H., Lasser, I., Winklbaur, B., Schlögelhofer, M., Riecher Rössler, A., Borgwardt, S., Walter, A., Harrisberger, F., Smieskova, R., Rapp, C., Ittig, S., Soguel Dit Piquard, F., Studerus, E., Klosterkötter, J., Ruhrmann, S., Paruch, J., Julkowski, D., Hilboll, D., Sham, P., Cherny, S., Chen, E., Campbell, D., Li, M., Romeo Casabona, C., Cirión, A., Mora, A., Jones, P., Kirkbride, J., Cannon, M., Rujescu, D., Tarricone, I., Berardi, D., Bonora, E., Seri, M., Marcacci, T., Chiri, L., Chierzi, F., Storbini, V., Braca, M., Minenna, M., Donegani, I., Fioritti, A., LA BARBERA, D., LA CASCIA, C., Mulè, A., Sideli, L., Sartorio, C., Ferraro, L., Tripoli, G., Seminerio, F., Marinaro, A., Mcgorry, P., Nelson, B., Amminger, G., Pantelis, C., Menezes, P., Del Ben, C., Tenan, S., Shuhama, R., Ruggeri, M., Tosato, S., Lasalvia, A., Bonetto, C., Ira, E., Nordentoft, M., Krebs, M., Barrantes Vidal, N., Cristóbal, P., Kwapil, T., Brietzke, E., Bressan, R., Gadelha, A., Maric, N., Andric, S., Mihaljevic, M., Mirjanic, T., Psychiatrie & Neuropsychologie, Promovendi MHN, and RS: MHeNs - R2 - Mental Health
- Subjects
URBANICITY ,Schizophrenia (object-oriented programming) ,CHILDHOOD ,Genome-wide association study ,VARIANTS ,Social Environment ,psychosi ,03 medical and health sciences ,0302 clinical medicine ,PSYCHOSIS ,epidemiology ,gene-environment interaction ,genetics ,psychosis ,schizophrenia ,SDG 3 - Good Health and Well-being ,RISK-FACTOR ,Settore M-PSI/08 - Psicologia Clinica ,Genetic variation ,Humans ,Genetic Predisposition to Disease ,GENOME-WIDE ASSOCIATION ,Gene ,Settore MED/25 - Psichiatria ,METAANALYSIS ,Scale (chemistry) ,Psychosis ,Genetic variants ,Environment and Schizophrenia Invited ,CANNABIS USE ,3. Good health ,030227 psychiatry ,Psychiatry and Mental health ,Evolutionary biology ,Identification (biology) ,Schizophrenic Psychology ,Population Risk ,genetic ,Psychology ,FOLLOW-UP ,030217 neurology & neurosurgery ,FUTURE-DIRECTIONS ,Clinical psychology - Abstract
European Community Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G x E), however, so far, thorough replication of findings is rare and G x E research still faces several conceptual and methodological challenges. in this article, we aim to review these recent developments and illustrate how integrated, large-scale investigations may overcome contemporary challenges in G x E research, drawing on the example of a large, international, multi-center study into the identification and translational application of G x E in schizophrenia. While such investigations are now well underway, new challenges emerge for G x E research from late-breaking evidence that genetic variation and environmental exposures are, to a significant degree, shared across a range of psychiatric disorders, with potential overlap in phenotype. Maastricht Univ, Med Ctr, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci,South Limburg Mental H, NL-6200 MD Maastricht, Netherlands Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England Mondriaan Mental Hlth Trust, Maastricht, Heerlen, Netherlands Univ Groningen, Univ Med Ctr Groningen, Rob Giel Clin Res, Univ Ctr Psychiat, Groningen, Netherlands Kings Coll London, Inst Psychiat, Dept Hlth Serv & Populat Res, London WC2R 2LS, England Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England Cardiff Univ, MRC, Ctr Neuropsychiat Genet, Cardiff CF10 3AX, S Glam, Wales Cent Inst Mental Hlth, Dept Psychiat & Psychotherapy, Mannheim, Germany Dokuz Eylul Univ, Sch Med, Dept Psychiat, Konak, Turkey Istanbul Univ, Istanbul Fac Med, Dept Psychiat, Psychot Disorders Res Unit, Istanbul, Turkey Ankara Univ, Sch Med, Dept Psychiat, Cebeci Hosp, TR-06100 Ankara, Turkey Ankara Univ, Brain Res Ctr, TR-06100 Ankara, Turkey Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA Middle E Tech Univ, Dept Psychol, TR-06531 Ankara, Turkey Diskapi YB Res & Training Hosp, Ankara, Turkey Turkish Federat Schizophrenia Assoc, Ankara, Turkey Ataturk Training & Res Hosp, Psychiat Clin, Ankara, Turkey Manisa Mental Hlth Hosp, Manisa, Turkey Istanbul Univ, Expt Med Res Inst, Dept Adv Neurol Sci, Istanbul Fac Med, Istanbul, Turkey Univ Complutense, IiSGM CIBERSAM, Dept Child & Adolescent Psychiat, Hosp Gen Univ Gregorio Maranon,Sch Med, E-28040 Madrid, Spain Univ Barcelona, Dept Psychiat, Hosp Clin, IDIBAPS,Ctr Invest Biomed Red Salud Mental CIBERS, Barcelona, Spain Univ Valencia, Sch Med, Dept Psychiat, Ctr Invest Biomed Red Salud Mental CIBERSAM, Valencia, Spain Univ Oviedo, Sch Med, Dept Med,Psychiat Area, Ctr Invest Biomed Red Salud Mental CIBERSAM, Oviedo, Spain Univ Santiago de Compostela, Dept Mental Hlth & Drug Addit Assistance, Hlth Serv Galicia,Psychiat Genet Grp IDIS, Hosp Clin,Ctr Invest Biomedica Red Salud Mental C, Santiago de Compostela 15706, Spain Hosp Virgen de la Luz, Serv Psiquiat, Dept Psychiat, Cuenca, Spain Hosp Univ Infanta Leonor Hosp Virgen Torre, Villa de Vallecas Mental Hlth Ctr, Villa de Vallecas Mental Hlth Dept, Madrid, Spain Hosp Univ Infanta Leonor Hosp Virgen Torre, Puente de Vallecas Mental Hlth Dept, Ctr Salud Mental Puente Vallecas, Madrid, Spain Hosp Clin Univ, Fdn Publ Galega Med Xenomica, Santiago de Compostela, Spain Univ Complutense, Sch Med, Hosp Gen Univ Gregorio Maranon, Dept Psychiat, E-28040 Madrid, Spain Hosp Psiquiatr Conxo, Santiago de Compostela, Spain Univ Amsterdam, Acad Med Ctr, Early Psychosis Sect, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands EMGO Inst Hlth & Care Res, Amsterdam, Netherlands Parnassia Psychiat Inst, Dept Psychosis Res, the Hague, Netherlands Rivierduinen Psychiat Inst, Leiden, Netherlands Grp Hosp Mondor, AP HP, Creteil, France Hop Henri Mondor, INSERM, U955, Equipe 15, F-94010 Creteil, France Univ Paris Est, Fac Med, Creteil, France Fdn Fondamental, Creteil, France CMP B CHU, F-63003 Clermont Ferrand 1, France Univ Auvergne, EA 7280, Clermont Ferrand, France EPS Maison Blanche, Paris, France UPC KU Leuven, Dept Neurosci, UPC, Kortenberg, Belgium UPC, Dept Neurosci, Res Grp Psychiat, Leuven, Belgium Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Human Genet, Leuven, Belgium Assoc Sci Res Multiple Births, Ghent, Belgium Univ Ghent, Dept Neurol, Ghent Univ Hosp, B-9000 Ghent, Belgium Univ Athens, Sch Med, Eginit Hosp, Athens 11528, Greece Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria Psychiat Univ Clin Basel, Ctr Gender Res & Early Detect, Basel, Switzerland Psychiat Univ Clin Basel, Diagnost & Crisis Intervent Ctr, Basel, Switzerland Univ Cologne, Dept Psychiat & Psychotherapy, D-50931 Cologne, Germany Univ Hong Kong, Li Ka Shing Fac Med, Ctr Genom Sci, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China Univ Basque Country, Univ Deusto, Interuniv Chair Law & Human Genome Prov Govt Bisk, Bilbao, Bizkaia, Spain Univ Zaragoza, Zaragoza, Spain Univ Cambridge, Dept Psychiat, Cambridge, England UCL, Div Psychiat, London, England Royal Coll Surgeons Ireland, Beaumont Hosp, Educ & Res Ctr, Dept Psychiat, Dublin 9, Ireland Univ Munich, Dept Psychiat, Div Mol & Clin Neurobiol, Munich, Germany Univ Bologna, Alma Mater Studiorium, Psychiat Unit, Dept Med & Surg Sci, Bologna, Italy Univ Bologna, Alma Mater Studiorium, Genet Unit, Dept Med & Surg Sci, Bologna, Italy Local Hlth Trust, Dept Mental Hlth & Pathol Addict, Bologna, Italy Univ Palermo, Sect Psychiat, Dept Expt Biomed & Clin Neurosci, Palermo, Italy P Giaccone Gen Hosp, Unit Psychiat, Palermo, Italy Univ Melbourne, Ctr Youth Mental Hlth, Parkville, Vic 3052, Australia Univ Melbourne, Melbourne Neuropsychiat Ctr, Carlton, Vic, Australia Univ São Paulo, Fac Med, Dept Med Prevent, BR-01246903 São Paulo, Brazil Univ São Paulo, Nucleo Pesquina Saude Mental Populac, São Paulo, Brazil Univ São Paulo, Fac Med Ribeirao Preto, Dept Neurociencias & Ciencias Comportamento, BR-14049 Ribeirao Preto, Brazil Univ Verona, Sect Psychiat, Dept Publ Hlth & Community Med, I-37100 Verona, Italy Copenhagen Univ Hosp, Res Unit, Mental Hlth Ctr Copenhagen, Copenhagen, Denmark Univ Paris 05, Fac Med, Serv Hosp Univ, Hop St Anne, Paris, France Univ Autonoma Barcelona, Dept Psicol Clin & Salut, E-08193 Barcelona, Spain St Pere Claver Fundacio Sanitaria, Dept Salut Mental, Barcelona, Spain Univ N Carolina, Dept Psychol, Greensboro, NC 27412 USA CIBERSAM, Spanish Mental Hlth Res Network, Barcelona, Spain Universidade Federal de São Paulo, Dept Psychiat, PRISMA Early Intervent Program, São Paulo, Brazil Univ Belgrade, Sch Med, Beograd, Serbia Universidade Federal de São Paulo, Dept Psychiat, PRISMA Early Intervent Program, São Paulo, Brazil European Community: HEALTH-F2-2009-241909 Web of Science
- Published
- 2014
- Full Text
- View/download PDF
57. Jumping to conclusions, general intelligence, and psychosis liability: Findings from the multi-centre EU-GEI case-control study
- Author
-
Fabio Seminerio, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Domenico Berardi, Jean-Paul Selten, Ilaria Tarricone, Peter B. Jones, Graham K. Murray, Miguel Bernardo, José Luis Santos, Pierre-Michel Llorca, Alexander Richards, Caterina La Cascia, Celso Arango, Manuel Arrojo, Victoria Rodriguez, Lieuwe de Haan, Craig Morgan, Crocettarachele Sartorio, Michael Conlon O'Donovan, Andrea Tortelli, Laura Ferraro, Julio Sanjuán, Robin M. Murray, Hannah E. Jongsma, Marta Di Forti, Cristina Marta Del-Ben, Eva Velthorst, Jim van Os, Daniele La Barbera, Bart P. F. Rutten, Julio Bobes, Sarah Tosato, Pak C. Sham, James B. Kirkbride, Paulo Rossi Menezes, Charlotte Gayer-Anderson, Giada Tripoli, Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Tripoli G., Quattrone D., Ferraro L., Gayer-Anderson C., Rodriguez V., La Cascia C., La Barbera D., Sartorio C., Seminerio F., Tarricone I., Berardi D., Szoke A., Arango C., Tortelli A., Llorca P.-M., De Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Jongsma H.E., Kirkbride J.B., Lasalvia A., Tosato S., Richards A., O'donovan M., Rutten B.P.F., Os J.V., Morgan C., Sham P.C., Murray R.M., Murray G.K., Di Forti M., Adult Psychiatry, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, Tripoli, Giada, Quattrone, Diego, Ferraro, Laura, Gayer-Anderson, Charlotte, Rodriguez, Victoria, La Cascia, Caterina, La Barbera, Daniele, Sartorio, Crocettarachele, Seminerio, Fabio, Tarricone, Ilaria, Berardi, Domenico, Szöke, Andrei, Arango, Celso, Tortelli, Andrea, Llorca, Pierre-Michel, de Haan, Lieuwe, Velthorst, Eva, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, Jose Lui, Arrojo, Manuel, Del-Ben, Cristina Marta, Menezes, Paulo Rossi, Selten, Jean-Paul, Jones, Peter B, Jongsma, Hannah E, Kirkbride, James B, Lasalvia, Antonio, Tosato, Sarah, Richards, Alex, O'Donovan, Michael, Rutten, Bart Pf, Os, Jim van, Morgan, Craig, Sham, Pak C, Murray, Robin M, Murray, Graham K, Di Forti, Marta, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: MA Psychiatrie (3), and MUMC+: Hersen en Zenuw Centrum (3)
- Subjects
Male ,MISCOMPREHENSION ,Intelligence ,DELÍRIO ,0302 clinical medicine ,Cognition ,SCHIZOPHRENIA ,psychotic-like experience ,jumping to conclusions ,Applied Psychology ,Problem Solving ,RISK ,education.field_of_study ,Middle Aged ,16. Peace & justice ,Cognitive bias ,3. Good health ,First episode psychosis ,IQ ,polygenic risk score ,psychotic-like experiences ,symptom dimensions ,Psychiatry and Mental health ,BIAS ,Schizophrenia ,RELIABILITY ,Female ,Original Article ,jumping to conclusion ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,medicine.symptom ,Clinical psychology ,Adult ,Psychosis ,Adolescent ,DISORDERS ,Population ,REEXAMINATION ,Delusions ,03 medical and health sciences ,Young Adult ,PEOPLE ,medicine ,Humans ,Cognitive Dysfunction ,education ,DELUSIONAL IDEATION ,Cognitive deficit ,business.industry ,Case-control study ,medicine.disease ,First episode psychosi ,030227 psychiatry ,Psychotic Disorders ,Case-Control Studies ,Jumping to conclusions ,business ,030217 neurology & neurosurgery - Abstract
This study was funded by the Medical Research Council, the European Community’s Seventh Framework Program grant [agreement HEALTH-F2-2009-241909 (Project EU-GEI)], São Paulo Research Foundation (grant 2012/0417-0), the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London, the NIHR BRC at University College London and the Wellcome Trust (grant 101272/Z/12/Z)., Tripoli, G., Quattrone, D., Ferraro, L., Gayer-Anderson, C., Rodriguez, V., La Cascia, C., La Barbera, D., Sartorio, C., Seminerio, F., Tarricone, I., Berardi, D., Szöke, A., Arango, C., Tortelli, A., Llorca, P.-M., De Haan, L., Velthorst, E., Bobes, J., Bernardo, M., Sanjuán, J., Santos, J.L., Arrojo, M., Del-Ben, C.M., Menezes, P.R., Selten, J.-P., Jones, P.B., Jongsma, H.E., Kirkbride, J.B., Lasalvia, A., Tosato, S., Richards, A., O'donovan, M., Rutten, B.P.F., Os, J.V., Morgan, C., Sham, P.C., Murray, R.M., Murray, G.K., Di Forti, M.
- Published
- 2021
- Full Text
- View/download PDF
58. The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study
- Author
-
Lieuwe de Haan, Jim van Os, Bart P. F. Rutten, Sarah Tosato, Caterina La Cascia, Craig Morgan, Andrei Szöke, Ilaria Tarricone, Antonio Lasalvia, Diego Quattrone, Els van der Ven, Miguel Bernardo, James B. Kirkbride, Peter B. Jones, Eva Velthorst, Julio Sanjuán, Manuel Arrojo, Domenico Berardi, Charlotte Gayer-Anderson, Jean-Paul Selten, Fabian Termorshuizen, Pierre-Michel Llorca, Robin M. Murray, Hannah E Jongsma, Clinical Developmental Psychology, APH - Mental Health, World Health Organization (WHO) Collaborating Center, Termorshuizen F., Van Der Ven E., Tarricone I., Jongsma H.E., Gayer-Anderson C., Lasalvia A., Tosato S., Quattrone D., La Cascia C., Szoke A., Berardi D., Llorca P.-M., De Haan L., Velthorst E., Bernardo M., Sanjuan J., Arrojo M., Murray R.M., Rutten B.P., Jones P.B., Van Os J., Kirkbride J.B., Morgan C., Selten J.-P., Adult Psychiatry, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, RS: MHeNs - R3 - Neuroscience, and MUMC+: MA Psychiatrie (3)
- Subjects
medicine.medical_specialty ,Dopamine ,Region of origin ,Ethnic group ,migration ,psychosi ,stress ,03 medical and health sciences ,Race (biology) ,0302 clinical medicine ,Epidemiology ,medicine ,Humans ,psychosis ,10. No inequality ,race ,Minority Groups ,Applied Psychology ,Transients and Migrants ,High rate ,Incidence ,Incidence (epidemiology) ,Social environment ,PREVALENCE ,030227 psychiatry ,3. Good health ,Europe ,schizophrenia ,Psychiatry and Mental health ,Geography ,Psychotic Disorders ,Multinational corporation ,1ST-CONTACT INCIDENCE ,ethnicity ,epidemiology ,030217 neurology & neurosurgery ,SOCIAL DEFEAT HYPOTHESIS ,Demography - Abstract
BackgroundIn Europe, the incidence of psychotic disorder is high in certain migrant and minority ethnic groups (hence: ‘minorities’). However, it is unknown how the incidence pattern for these groups varies within this continent. Our objective was to compare, across sites in France, Italy, Spain, the UK and the Netherlands, the incidence rates for minorities and the incidence rate ratios (IRRs, minorities v. the local reference population).MethodsThe European Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI) study was conducted between 2010 and 2015. We analyzed data on incident cases of non-organic psychosis (International Classification of Diseases, 10th edition, codes F20–F33) from 13 sites.ResultsThe standardized incidence rates for minorities, combined into one category, varied from 12.2 in Valencia to 82.5 per 100 000 in Paris. These rates were generally high at sites with high rates for the reference population, and low at sites with low rates for the reference population. IRRs for minorities (combined into one category) varied from 0.70 (95% CI 0.32–1.53) in Valencia to 2.47 (95% CI 1.66–3.69) in Paris (test for interaction: p = 0.031). At most sites, IRRs were higher for persons from non-Western countries than for those from Western countries, with the highest IRRs for individuals from sub-Saharan Africa (adjusted IRR = 3.23, 95% CI 2.66–3.93).ConclusionsIncidence rates vary by region of origin, region of destination and their combination. This suggests that they are strongly influenced by the social context.
- Published
- 2020
- Full Text
- View/download PDF
59. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study
- Author
-
Victoria Rodriguez, Luis Alameda, Diego Quattrone, Giada Tripoli, Charlotte Gayer-Anderson, Edoardo Spinazzola, Giulia Trotta, Hannah E. Jongsma, Simona Stilo, Caterina La Cascia, Laura Ferraro, Daniele La Barbera, Antonio Lasalvia, Sarah Tosato, Ilaria Tarricone, Elena Bonora, Stéphane Jamain, Jean-Paul Selten, Eva Velthorst, Lieuwe de Haan, Pierre-Michel Llorca, Manuel Arrojo, Julio Bobes, Miguel Bernardo, Celso Arango, James Kirkbride, Peter B. Jones, Bart P. Rutten, Alexander Richards, Pak C. Sham, Michael O'Donovan, Jim Van Os, Craig Morgan, Marta Di Forti, Robin M. Murray, Evangelos Vassos, Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, Rodriguez, V, Alameda, L, Quattrone, D, Tripoli, G, Gayer-Anderson, C, Spinazzola, E, Trotta, G, Jongsma, HE, Stilo, S, La Cascia, C, Ferraro, L, La Barbera, D, Lasalvia, A, Tosato, S, Tarricone, I, Bonora, E, Jamain, S, Selten, JP, Velthorst, E, de Haan, L, Llorca, PM, Arrojo, M, Bobes, J, Bernardo, M, Arango, C, Kirkbride, J, Jones, PB, Rutten, BP, Richards, A, Sham, PC, O'Donovan, M, Van Os, J, Morgan, C, Di Forti, M, Murray, RM, Vassos, E, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, RS: MHeNs - R3 - Neuroscience, and MUMC+: MA Psychiatrie (3)
- Subjects
bipolar disorder ,Affective psychosis ,diagnosis ,GENETIC-RELATIONSHIPS ,schizophrenia-spectrum disorder ,Psychiatry and Mental health ,Affective psychosis, bipolar disorder, diagnosis, genetics, polygenic score, psychosis, psychotic depression, schizophrenia-spectrum disorder ,LIABILITY ,psychotic depression ,genetics ,polygenic score ,psychosis ,GENOME-WIDE ASSOCIATION ,Applied Psychology - Abstract
This work was supported by funding from the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). (...) CA was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso and Fundación Alicia Koplowitz. MB was supported by the Ministry of Economy and Competitivity (PI08/0208; PI11/00325; PI14/00612), Instituto de Salud Carlos III – ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM, by the CERCA Programme/Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l’any 2017 de concessió de subvencions del PERIS 2016-2020, modalitat Projectes de recerca orientats a l’atenció primària, amb el codi d’expedient SLT006/17/00345; and grateful for the support of the Institut de Neurociències, Universitat de Barcelona., Rodriguez V., Alameda L., Quattrone D., Tripoli G., Gayer-Anderson C., Spinazzola E., Trotta G., Jongsma H.E., Stilo S., La Cascia C., Ferraro L., La Barbera D., Lasalvia A., Tosato S., Tarricone I., Bonora E., Jamain S., Selten J.-P., Velthorst E., De Haan L., Llorca P.-M., Arrojo M., Bobes J., Bernardo M., Arango C., Kirkbride J., Jones P.B., Rutten B.P., Richards A., Sham P.C., O'Donovan M., Van Os J., Morgan C., Di Forti M., Murray R.M., Vassos E.
- Published
- 2022
- Full Text
- View/download PDF
60. The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study
- Author
-
James B. Kirkbride, Hannah E. Jongsma, Alastair G. Cardno, Paulo Rossi Menezes, Andrea Quattrone, Pierre-Michel Llorca, Jose Luis Santos, Ilaria Tarricone, F. Seminerio, Charlotte Gayer-Anderson, Lucia Sideli, Roberto Muratori, Daniele La Barbera, G Tripoli, Teresa Sánchez-Gutiérrez, Jim van Os, Bart P. F. Rutten, Miguel Bernardo, Marta Di Forti, Robin M. Murray, Sarah Tosato, Julio Sanjuán, Lieuwe de Haan, Manuel Arrojo, Crocettarachele Sartorio, Eva Velthorst, Andrei Szöke, Antonio Lasalvia, Julio Bobes, Diego Quattrone, Craig Morgan, Ulrich Reininghaus, Victoria Rodriguez, Evangelos Vassos, Jean-Paul Selten, Giovanna Marrazzo, Caterina La Cascia, Celso Arango, Cristina Marta Del-Ben, Andrea Tortelli, Laura Ferraro, Peter B. Jones, RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, Università degli studi di Palermo - University of Palermo, Faculty of Health Science, Universidad Internacional de la Rioja (UNIR), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Barcelona Clinic Schizophrenia Unit, Department of Medicine, Neuroscience Institute, Hospital clinic, University of Barcelona, IDIBAPS, CIBERSAM, Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Universidade de São Paulo Medical School (FMUSP), Department of Health Service and Population Research, Institute of Psychiatry, King's College London, Psylife Group, Division of Psychiatry, University College London, 6th Floor, Maple House, Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata di Verona, Università degli studi di Verona = University of Verona (UNIVR), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Department of Psychiatry, Servicio de Psiquiatría Hospital 'Virgen de la Luz', Universitat de València (UV), Rivierduinen Institute for Mental Health Care, Institut National de la Santé et de la Recherche Médicale (INSERM), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Dapertment of Mental Health and pathological addictions, Bologna Local Health Authority, Etablissement Public de Santé Maison Blanche, Department of Psychiatry, Early Psychosis Section, Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, National Health Service, Villa Betania Institute, Department of Psychiatry, University of Cambridge, Cambridge, UK, Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, University of Leeds, South London and Maudsley NHS Mental Health Foundation Trust, Tournayre, Christophe, Ferraro L., La Cascia C., La Barbera D., Sanchez-Gutierrez T., Tripoli G., Seminerio F., Sartorio C., Marrazzo G., Sideli L., Arango C., Arrojo M., Bernardo M., Bobes J., Del-Ben C.M., Gayer-Anderson C., Jongsma H.E., Kirkbride J.B., Lasalvia A., Tosato S., Llorca P.-M., Menezes P.R., Rutten B.P., Santos J.L., Sanjuan J., Selten J.-P., Szoke A., Tarricone I., Muratori R., Tortelli A., Velthorst E., Rodriguez V., Quattrone A., Jones P.B., Van Os J., Vassos E., Morgan C., de Haan L., Reininghaus U., Cardno A.G., Di Forti M., Murray R.M., Quattrone D., Jones, Peter [0000-0002-0387-880X], Apollo - University of Cambridge Repository, University College of London [London] (UCL), University of Cambridge [UK] (CAM), Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, and Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep
- Subjects
Psychosis ,First episode psychosis ,cognitive domains ,Premorbid Adjustment Scale ,QUOCIENTE DE INTELIGÊNCIA ,Transdiagnostic Premorbid adjustment ,NEGATIVE SYMPTOMS ,Article ,symptom dimensions ,premorbid adjustment ,WORKING-MEMORY ,Secondary analysis ,first episode psychosis ,1ST-EPISODE NONAFFECTIVE PSYCHOSIS ,Medicine ,Scopus ,Cognitive domain ,[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Settore MED/25 - Psichiatria ,Biological Psychiatry ,Transdiagnostic ,business.industry ,Working memory ,Confounding ,Cognitive domains ,Cognition ,BIPOLAR DISORDER ,Symptom dimensions ,medicine.disease ,GENE-ENVIRONMENT INTERACTIONS ,First episode psychosi ,CANNABIS USE ,Psychiatry and Mental health ,Symptom dimension ,Perceptual reasoning ,JCR ,IQ ,SOCIAL COGNITION ,transdiagnostic ,PROCESSING-SPEED ,NEURODEVELOPMENTAL TRAJECTORIES ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Premorbid adjustment ,business ,SCHIZOAFFECTIVE DISORDER ,Clinical psychology - Abstract
Premorbid functioning and cognitive measures may reflect gradients of developmental impairment across diagnostic categories in psychosis. In this study, we sought to examine the associations of current cognition and premorbid adjustment with symptom dimensions in a large first episode psychosis (FEP) sample. We used data from the international EU-GEI study. Bifactor modelling of the Operational Criteria in Studies of Psychotic Illness (OPCRIT) ratings provided general and specific symptom dimension scores. Premorbid Adjustment Scale estimated premorbid social (PSF) and academic adjustment (PAF), and WAIS-brief version measured IQ. A MANCOVA model examined the relationship between symptom dimensions and PSF, PAF, and IQ, having age, sex, country, self-ascribed ethnicity and frequency of cannabis use as confounders. In 785 patients, better PSF was associated with fewer negative (B=-0.12, 95% C.I. -0.18, -0.06, p
- Published
- 2021
- Full Text
- View/download PDF
61. Migration history and risk of psychosis: results from the multinational EU-GEI study
- Author
-
Iulio Sanjuán, Robin M. Murray, Els van der Ven, James B. Kirkbride, Hannah E Jongsma, Jean-Paul Selten, Manuel Arrojo, Julio Bobes, Andrei Szöke, Cristina Marta Del-Ben, Roberto Muratori, Jim van Os, Mara Parellada, Bart P. F. Rutten, Craig Morgan, Pierre-Michel Llorca, Marta Di Forti, Sarah Tosato, Peter B. Jones, Miguel Bernardo, Ilaria Tarricone, Simona A. Stilo, Jose Luis Santos, Federico Suprani, Conrad Iyegbe, Giuseppe D’Andrea, Eva Velthorst, Domenico Berardi, Paulo Rossi Menezes, Andrea Tortelli, Laura Ferraro, Antonio Lasalvia, Diego Quattrone, Caterina La Cascia, Celso Arango, Lieuwe de Haan, Charlotte Gayer-Anderson, Giada Tripoli, University of Bologna/Università di Bologna, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), University College of London [London] (UCL), University of Cambridge [UK] (CAM), Università degli studi di Verona = University of Verona (UNIVR), King‘s College London, Institute of Psychiatry, Psychology & Neuroscience, King's College London, Columbia University [New York], Department of Psychiatry and Neuropsychology [Maastricht], Maastricht University [Maastricht], VU University Medical Center [Amsterdam], Icahn School of Medicine at Mount Sinai [New York] (MSSM), Universidade de São Paulo = University of São Paulo (USP), Hospital General Universitario 'Gregorio Marañón' [Madrid], Centro de Investigación Biomédica en Red Salud Mental [Madrid] (CIBER-SAM), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Università degli studi di Palermo - University of Palermo, Universidad de Oviedo [Oviedo], University of Barcelona, Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne] (CHUS), Instituto de Investigación Sanitaria de Santiago de Compostela / Health Research Institute of Santiago de Compostela (IDIS), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), University Medical Center [Utrecht], Cambridgeshire & Peterborough NHS Foundation Trust [Cambridge] (CPFT), RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R3 - Neuroscience, Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Tarricone I., D'Andrea G., Jongsma H.E., Tosato S., Gayer-Anderson C., Stilo S.A., Suprani F., Iyegbe C., Van Der Ven E., Quattrone D., Di Forti M., Velthorst E., Rossi Menezes P., Arango C., Parellada M., Lasalvia A., La Cascia C., Ferraro L., Bobes J., Bernardo M., Sanjuan I., Santos J.L., Arrojo M., Del-Ben C.M., Tripoli G., Llorca P.-M., De Haan L., Selten J.-P., Tortelli A., Szoke A., Muratori R., Rutten B.P., Van Os J., Jones P.B., Kirkbride J.B., Berardi D., Murray R.M., Morgan C., Clinical Developmental Psychology, World Health Organization (WHO) Collaborating Center, and Tournayre, Christophe
- Subjects
Psychosis ,medicine.medical_specialty ,ESTUDOS DE CASOS E CONTROLES ,Ethnic group ,Logistic regression ,IMMIGRANTS ,FAMILY-HISTORY ,first-generation migrants ,Odds ,03 medical and health sciences ,0302 clinical medicine ,First-episode psychosi ,first-generation migrant ,SCHIZOPHRENIA ,medicine ,migration adversities ,[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,1ST-EPISODE PSYCHOSIS ,INTERNAL MIGRATION ,Applied Psychology ,Cumulative effect ,ComputingMilieux_MISCELLANEOUS ,migration history ,psychosis risk ,business.industry ,Public health ,migration adversitie ,SDG 10 - Reduced Inequalities ,First-episode psychosis ,medicine.disease ,CHILDHOOD TRAUMA ,030227 psychiatry ,3. Good health ,ETHNICITY ,Psychiatry and Mental health ,social disadvantages ,Schizophrenia ,Multinational corporation ,1ST-CONTACT INCIDENCE ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,business ,MENTAL-HEALTH ,SOCIAL DISADVANTAGE ,030217 neurology & neurosurgery ,Demography - Abstract
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme., Tarricone, I., D'Andrea, G., Jongsma, H.E., Tosato, S., Gayer-Anderson, C., Stilo, S.A., Suprani, F., Iyegbe, C., Van Der Ven, E., Quattrone, D., Di Forti, M., Velthorst, E., Rossi Menezes, P., Arango, C., Parellada, M., Lasalvia, A., La Cascia, C., Ferraro, L., Bobes, J., Bernardo, M., Sanjuán, I., Santos, J.L., Arrojo, M., Del-Ben, C.M., Tripoli, G., Llorca, P.-M., De Haan, L., Selten, J.-P., Tortelli, A., Szöke, A., Muratori, R., Rutten, B.P., Van Os, J., Jones, P.B., Kirkbride, J.B., Berardi, D., Murray, R.M., Morgan, C.
- Published
- 2021
- Full Text
- View/download PDF
62. Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: Results from the EU-GEI case-control study
- Author
-
Robin M. Murray, Hannah E Jongsma, Ilaria Tarricone, Els van der Ven, Domenico Berardi, Julio Bobes, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Peter B. Jones, Manuel Arrojo, Jose Luis Santos, Lieuwe de Haan, Craig Morgan, Caterina La Cascia, Miguel Bernardo, Celso Arango, Marta Di Forti, Julio Sanjuán, Andrea Tortelli, Paulo Rossi Menezes, Charlotte Gayer-Anderson, Christina Marta Del-Ben, Eva Velthorst, James B. Kirkbride, Jim van Os, Bart P. F. Rutten, Jongsma H.E., Gayer-Anderson C., Tarricone I., Velthorst E., Van Der Ven E., Quattrone D., Di Forti M., Menezes P.R., Del-Ben C.M., Arango C., Lasalvia A., Berardi D., La Cascia C., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., De Haan L., Tortelli A., Szoke A., Murray R.M., Rutten B.P., Van Os J., Morgan C., Jones P.B., Kirkbride J.B., ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Adult Psychiatry, APH - Mental Health, Clinical Developmental Psychology, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, RS: MHeNs - R3 - Neuroscience, MUMC+: MA Psychiatrie (3), and MUMC+: Hersen en Zenuw Centrum (3)
- Subjects
Male ,Social Determinants of Health ,Ethnic group ,Poison control ,IMMIGRANTS ,Occupational safety and health ,0302 clinical medicine ,psychotic disorders ,SCHIZOPHRENIA ,Discrimination ,Odds Ratio ,Applied Psychology ,RISK ,HYPOTHESIS ,Communication Barriers ,Linguistic distance ,Middle Aged ,epidemiology ,ethnicity ,social disadvantage ,3. Good health ,Social research ,Europe ,Psychiatry and Mental health ,MIGRANT GROUPS ,Female ,STRIATAL DOPAMINE FUNCTION ,Adult ,Adolescent ,DISORDERS ,1ST EPISODE ,Black People ,Library science ,TRANSTORNOS PSICÓTICOS ,White People ,Young Adult ,03 medical and health sciences ,First episode psychosis ,Political science ,Humans ,Minority status ,INCIDENCE RATES ,Health Status Disparities ,Original Articles ,psychotic disorder ,030227 psychiatry ,Case-Control Studies ,Ethnic and Racial Minorities ,IDENTITY ,Gene-Environment Interaction ,Social disadvantage ,030217 neurology & neurosurgery - Abstract
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme. The Brazilian study was funded by grant 2012-0417-0 from the São Paulo Research Foundation. Dr Jongsma is funded by the Economic and Social Research Council (grant ES/S011714/1). Dr Kirkbride is funded by the Wellcome Trust and Royal Society (Grant 101272/Z/13/Z). Dr Jongsma and Professor Jones are funded by the National Institute of Health Research Collaboration of Leadership in Applied Health Research and Care East of England. Professor Rutten is funded by the Netherlands Scientific Organisation (VIDI award number 91718336). Dr Jongsma and Dr Kirkbride are supported by the National Institute for Health Research, University College London Hospital, Biomedical Research Centre., Jongsma, H.E., Gayer-Anderson, C., Tarricone, I., Velthorst, E., Van Der Ven, E., Quattrone, D., Di Forti, M., Menezes, P.R., Del-Ben, C.M., Arango, C., Lasalvia, A., Berardi, D., La Cascia, C., Bobes, J., Bernardo, M., Sanjuán, J., Santos, J.L., Arrojo, M., De Haan, L., Tortelli, A., Szöke, A., Murray, R.M., Rutten, B.P., Van Os, J., Morgan, C., Jones, P.B., Kirkbride, J.B.
- Published
- 2021
- Full Text
- View/download PDF
63. Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis
- Author
-
Robin M. Murray, Luis Alameda, Andrea Tortelli, Laura Ferraro, Cristina Marta Del-Ben, Eva Velthorst, Peter B. Jones, Monica Aas, James B. Kirkbride, Pierre-Michel Llorca, Evangelos Vassos, Hannah E. Jongsma, Paola Dazzan, Jean-Paul Selten, Miguel Bernardo, Victoria Rodriguez, Lieuwe de Haan, Marta Di Forti, Jose Luis Santos, Roberto Muratori, Caterina La Cascia, Manuel Arrojo, Pak C. Sham, Jim van Os, Bart P. F. Rutten, Daniele La Barbera, Celso Arango, Ilaria Tarricone, Domenico Berardi, Sarah Tosato, Craig Morgan, Julio Bobes, Paulo Rossi Menezes, Antonella Trotta, Julio Sanjuán, Andrei Szöke, Antonio Lasalvia, Diego Quattrone, Charlotte Gayer-Anderson, Giada Tripoli, Aas M., Alameda L., Di Forti M., Quattrone D., Dazzan P., Trotta A., Ferraro L., Rodriguez V., Vassos E., Sham P., Tripoli G., La Cascia C., La Barbera D., Tarricone I., Muratori R., Berardi D., Lasalvia A., Tosato S., Szoke A., Llorca P.-M., Arango C., Tortelli A., De Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Jongsma H.E., Kirkbride J.B., Rutten B.P.F., Van Os J., Gayer-Anderson C., Murray R.M., Morgan C., Cascia C.L., Barbera D.L., RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep
- Subjects
SCHIZOPHRENIA SPECTRUM ,medicine.medical_specialty ,GENES ,polygenic risk ,first-episode psychosi ,ILLNESS ,interaction contrast ratio ,Childhood trauma ,DOPAMINE ,First episode psychosis ,Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat ,MALTREATMENT ,Medicine ,first-episode psychosis ,ABUSE ,Psychiatry ,Settore MED/25 - Psichiatria ,Applied Psychology ,TRAUMA ,ENVIRONMENT ,business.industry ,medicine.disease ,schizophrenia ,Psychiatry and Mental health ,Schizophrenia ,RELIABILITY ,Polygenic risk score ,synergistic effects ,business - Abstract
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme., Aas, M; Alameda, L; Di Forti, M; Quattrone, D; Dazzan, P; Trotta, A; Ferraro, L; Rodriguez, V; Vassos, E; Sham, P; Tripoli, G; La Cascia, C; La Barbera, D; Tarricone, I; Muratori, R; Berardi, D; Lasalvia, A; Tosato, S; Szoke, A; Llorca, PM; Arango, C; Tortelli, A; de Haan, L; Velthorst, E; Bobes, J; Bernardo, M; Sanjuan, J; Santos, JL; Arrojo, M; Del-Ben, CM; Menezes, PR; Selten, JP; Jones, PB; Jongsma, HE; Kirkbride, JB; Rutten, BPF; van Os, J; Gayer-Anderson, C; Murray, RM; Morgan, C
- Published
- 2021
64. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study
- Author
-
Quattrone, Diego, Reininghaus, Ulrich, Richards, Alex L., Tripoli, Giada, Ferraro, Laura, Quattrone, Andrea, Marino, Paolo, Rodriguez, Victoria, Spinazzola, Edoardo, Gayer-Anderson, Charlotte, Jongsma, Hannah E., Jones, Peter B., La Cascia, Caterina, La Barbera, Daniele, Tarricone, Ilaria, Bonora, Elena, Tosato, Sarah, Lasalvia, Antonio, Szöke, Andrei, Arango, Celso, Bernardo, Miquel, Bobes, Julio, Del Ben, Cristina Marta, Menezes, Paulo Rossi, Llorca, Pierre-Michel, Santos, Jose Luis, Sanjuán, Julio, Arrojo, Manuel, Tortelli, Andrea, Velthorst, Eva, Berendsen, Steven, de Haan, Lieuwe, Rutten, Bart P. F., Lynskey, Michael T., Freeman, Tom P., Kirkbride, James B., Sham, Pak C., O'Donovan, Michael C., Cardno, Alastair G., Vassos, Evangelos, van Os, Jim, Morgan, Craig, Murray, Robin M., Lewis, Cathryn M., Di Forti, Marta, Hubbard, Kathryn, Beards, Stephanie, Stilo, Simona A., Parellada, Mara, Fraguas, David, Castro, Marta Rapado, Andreu-Bernabeu, Álvaro, López, Gonzalo, Matteis, Mario, González, Emiliano, Durán-Cutilla, Manuel, Díaz-Caneja, Covadonga M., Cuadrado, Pedro, Rodríguez Solano, José Juan, Carracedo, Angel, Costas, Javier, Sánchez, Emilio, Amoretti, Silvia, Lorente-Rovira, Esther, Garcia-Portilla, Paz, Jiménez-López, Estela, Franke, Nathalie, van Dam, Daniella, Termorshuizen, Fabian, van der Ven, Elsje, Messchaart, Elles, Leboyer, Marion, Schu?rhoff, Franck, Jamain, Stéphane, Baudin, Grégoire, Ferchiou, Aziz, Pignon, Baptiste, Richard, Jean-Romain, Charpeaud, Thomas, Tronche, Anne-Marie, Frijda, Flora, Marrazzo, Giovanna, Sideli, Lucia, Sartorio, Crocettarachele, Seminerio, Fabio, Loureiro, Camila Marcelino, Shuhama, Rosana, Ruggeri, Mirella, Bonetto, Chiara, Cristofalo, Doriana, Berardi, Domenico, Seri, Marco, D?Andrea, Giuseppe, Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, RS: MHeNs - R3 - Neuroscience, MUMC+: MA Psychiatrie (3), MUMC+: Hersen en Zenuw Centrum (3), Quattrone D., Reininghaus U., Richards A.L., Tripoli G., Ferraro L., Quattrone A., Marino P., Rodriguez V., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Jones P.B., La Cascia C., La Barbera D., Tarricone I., Bonora E., Tosato S., Lasalvia A., Szoke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuan J., Arrojo M., Tortelli A., Velthorst E., Berendsen S., de Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Kirkbride J.B., Sham P.C., O'Donovan M.C., Cardno A.G., Vassos E., van Os J., Morgan C., Murray R.M., Lewis C.M., Di Forti M., Hubbard K., Beards S., Stilo S.A., Parellada M., Fraguas D., Castro M.R., Andreu-Bernabeu A., Lopez G., Matteis M., Gonzalez E., Duran-Cutilla M., Diaz-Caneja C.M., Cuadrado P., Rodriguez Solano J.J., Carracedo A., Costas J., Sanchez E., Amoretti S., Lorente-Rovira E., Garcia-Portilla P., Jimenez-Lopez E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schurhoff F., Jamain S., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Marrazzo G., Sideli L., Sartorio C., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Bonetto C., Cristofalo D., Berardi D., Seri M., D'Andrea G., Quattrone, Diego [0000-0002-6051-8309], Richards, Alex L [0000-0003-3218-7247], Marino, Paolo [0000-0003-3571-1753], Rodriguez, Victoria [0000-0003-0383-0846], Jones, Peter B [0000-0002-0387-880X], Tosato, Sarah [0000-0002-9665-7538], Bernardo, Miquel [0000-0001-8748-6717], Bobes, Julio [0000-0003-2187-4033], Del Ben, Cristina Marta [0000-0003-0145-9975], Menezes, Paulo Rossi [0000-0001-6330-3314], Llorca, Pierre-Michel [0000-0001-7438-8990], Rutten, Bart PF [0000-0002-9834-6346], Kirkbride, James B [0000-0003-3401-0824], O'Donovan, Michael C [0000-0001-7073-2379], Vassos, Evangelos [0000-0001-6363-0438], Murray, Robin M [0000-0003-0829-0519], Lewis, Cathryn M [0000-0002-8249-8476], Apollo - University of Cambridge Repository, Rutten, Bart P F [0000-0002-9834-6346], Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep
- Subjects
medicine.medical_specialty ,Psychosis ,Population ,Neurosciences. Biological psychiatry. Neuropsychiatry ,PHENOTYPES ,ILLNESS ,Psychotic Disorder ,Predictive markers ,Article ,Cellular and Molecular Neuroscience ,DEFICIT SYNDROME ,Risk Factors ,First episode psychosis ,medicine ,Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat ,Humans ,Cannabi ,Clinical genetics ,Genetic risk ,VALIDITY ,education ,Settore MED/25 - Psichiatria ,SCHEDULE ,Biological Psychiatry ,METAANALYSIS ,Cannabis ,UTILITY ,education.field_of_study ,Risk Factor ,ESQUIZOFRENIA ,ASSOCIATION ,Cannabis use ,medicine.disease ,BIFACTOR MODEL ,Psychiatry and Mental health ,Psychotic Disorders ,INTERRATER RELIABILITY ,Schizophrenia ,Linear Models ,Linear Model ,Medical genetics ,Polygenic risk score ,Psychology ,Human ,RC321-571 ,Clinical psychology - Abstract
The work was supported by Guarantors of Brain post-doctoral clinical fellowship to DQ; Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; Heisenberg professorship from the German Research Founda- tion (grant no. 389624707) to UR; the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0., Quattrone D., Reininghaus U., Richards A.L., Tripoli G., Ferraro L., Quattrone A., Marino P., Rodriguez V., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Jones P.B., La Cascia C., La Barbera D., Tarricone I., Bonora E., Tosato S., Lasalvia A., Szöke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuán J., Arrojo M., Tortelli A., Velthorst E., Berendsen S., de Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Kirkbride J.B., Sham P.C., O’Donovan M.C., Cardno A.G., Vassos E., van Os J., Morgan C., Murray R.M., Lewis C.M., Di Forti M., Hubbard K., Beards S., Stilo S.A., Parellada M., Fraguas D., Castro M.R., Andreu-Bernabeu Á., López G., Matteis M., González E., Durán-Cutilla M., Díaz-Caneja C.M., Cuadrado P., Rodríguez Solano J.J., Carracedo A., Costas J., Sánchez E., Amoretti S., Lorente-Rovira E., Garcia-Portilla P., Jiménez-López E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schürhoff F., Jamain S., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Marrazzo G., Sideli L., Sartorio C., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Bonetto C., Cristofalo D., Berardi D., Seri M., D’Andrea G.
- Published
- 2021
65. Pre-training inter-rater reliability of clinical instruments in an international psychosis research project
- Author
-
Steven Berendsen, Pim Kapitein, Frederike Schirmbeck, Mirjam J. van Tricht, Philip McGuire, Craig Morgan, Charlotte Gayer-Anderson, Matthew J. Kempton, Lucia Valmaggia, Diego Quattrone, Marta di Forti, Mark van der Gaag, James B. Kirkbride, Hannah E. Jongsma, Peter B. Jones, Maria Parellada, Celso Arango, Manuel Arrojo, Miguel Bernardo, Julio Sanjuán, José Luis Santos, Andrei Szöke, Andrea Tortelli, Pierre-Michel Llorca, Ilaria Tarricone, Giada Tripoli, Laura Ferraro, Caterina La Cascia, Antonio Lasalvia, Sarah Tosato, Paulo Rossi Menezes, Cristina Marta Del-Ben, Barnaby Nelson, Anita Riecher-Rössler, Rodrigo Bressan, Neus Barrantes-Vidal, Marie-Odile Krebs, Merete Nordentoft, Stephan Ruhrmann, Gabriele Sachs, Bart P.F. Rutten, Jim van Os, Eva Velthorst, Lieuwe de Haan, Maria Calem, Stefania Tognin, Gemma Modinos, Sara Pisani, Tamar C. Kraan, Daniella S. van Dam, Nadine Burger, Patrick McGorry, G. Paul Amminger, Athena Politis, Joanne Goodall, Stefan Borgwardt, Erich Studerus, Ary Gadelha, Elisa Brietzke, Graccielle Asevedo, Elson Asevedo, Andre Zugman, Tecelli Domínguez-Martínez, Manel Monsonet, Lidia Hinojosa, Paula Cristóbal-Narváez, Anna Racioppi, Thomas R. Kwapil, Mathilde Kazes, Claire Daban, Julie Bourgin, Olivier Gay, Célia Mam-Lam-Fook, Dorte Nordholm, Lasse Randers, Kristine Krakauer, Louise Birkedal Glenthøj, Birte Glenthøj, Dominika Gebhard, Julia Arnhold, Joachim Klosterkötter, Iris Lasser, Bernadette Winklbaur, Philippe A. Delespaul, Graduate School, Adult Psychiatry, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Compulsivity, Impulsivity & Attention, Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Berendsen S., Kapitein P., Schirmbeck F., van Tricht M.J., McGuire P., Morgan C., Gayer-Anderson C., Kempton M.J., Valmaggia L., Quattrone D., di Forti M., van der Gaag M., Kirkbride J.B., Jongsma H.E., Jones P.B., Parellada M., Arango C., Arrojo M., Bernardo M., Sanjuan J., Santos J.L., Szoke A., Tortelli A., Llorca P.-M., Tarricone I., Tripoli G., Ferraro L., La Cascia C., Lasalvia A., Tosato S., Menezes P.R., Del-Ben C.M., Nelson B., Riecher-Rossler A., Bressan R., Barrantes-Vidal N., Krebs M.-O., Nordentoft M., Ruhrmann S., Sachs G., Rutten B.P.F., van Os J., Velthorst E., de Haan L., Calem M., Tognin S., Modinos G., Pisani S., Kraan T.C., van Dam D.S., Burger N., McGorry P., Amminger G.P., Politis A., Goodall J., Borgwardt S., Studerus E., Gadelha A., Brietzke E., Asevedo G., Asevedo E., Zugman A., Dominguez-Martinez T., Monsonet M., Hinojosa L., Cristobal-Narvaez P., Racioppi A., Kwapil T.R., Kazes M., Daban C., Bourgin J., Gay O., Mam-Lam-Fook C., Nordholm D., Randers L., Krakauer K., Glenthoj L.B., Glenthoj B., Gebhard D., Arnhold J., Klosterkotter J., Lasser I., Winklbaur B., Delespaul P.A., RS: MHeNs - R3 - Neuroscience, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R2 - Mental Health, and MUMC+: Hersen en Zenuw Centrum (3)
- Subjects
Research design ,Psychosis ,INFORMATION ,IMPACT ,Applied psychology ,MEDLINE ,Assessor selection, Pre-training inter-rater reliability, Psychosis instruments ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Humans ,Biological Psychiatry ,ComputingMilieux_MISCELLANEOUS ,Observer Variation ,REPRODUTIBILIDADE DE RESULTADOS ,business.industry ,Pre-training inter-rater reliability ,Reproducibility of Results ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Inter-rater reliability ,Assessor selection ,TRIALS ,Psychotic Disorders ,Research Design ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,MEASUREMENT ERROR ,business ,Observer variation ,030217 neurology & neurosurgery ,Psychosis instruments - Abstract
International audience
- Published
- 2019
- Full Text
- View/download PDF
66. Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study
- Author
-
Misra, Supriya, Gelaye, Bizu, Koenen, Karestan C, Williams, David R, Borba, Christina PC, Quattrone, Diego, Di Forti, Marta, La Cascia, Caterina, La Barbera, Daniele, Tarricone, Ilaria, Berardi, Domenico, Szöke, Andrei, Arango, Celso, Tortelli, Andrea, De Haan, Lieuwe, Velthorst, Eva, Bobes, Julio, Bernardo, Miguel, Sanjuán, Julio, Santos, Jose Luis, Arrojo, Manuel, Del-Ben, Cristina Marta, Menezes, Paulo Rossi, Selten, Jean-Paul, Jones, Peter B, Kirkbride, James B, EU-GEI WP2 Group, Rutten, Bart PF, Van Os, Jim, Murray, Robin M, Gayer-Anderson, Charlotte, Morgan, Craig, Misra S., Gelaye B., Koenen K.C., Williams D.R., Borba C.P.C., Quattrone D., Di Forti M., La Cascia C., La Barbera D., Tarricone I., Berardi D., Szoke A., Arango C., Tortelli A., de Haan L., Velthorst E., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Selten J.-P., Jones P.B., Kirkbride J.B., Rutten B.P.F., Os J., Murray R.M., Gayer-Anderson C., Morgan C., Supriya Misra, Bizu Gelaye, Karestan C. Koenen, David R. Williams, Christina P.C. Borba, Diego Quattrone, Marta Di Forti, Caterina La Cascia, Daniele La Barbera, Ilaria Tarricone, Domenico Berardi, Andrei Szöke, Celso Arango, Andrea Tortelli, Lieuwe de Haan, Eva Velthorst, Julio Bobes, Miguel Bernardo, Julio Sanjuán, Jose Luis Santos, Manuel Arrojo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B. Jones, James B. Kirkbride, EU-GEI WP2 Group, Bart P.F. Rutten, Jim van Os, Robin M. Murray, Charlotte Gayer-Anderson, Craig Morgan, Misra, Supriya [0000-0003-0389-1227], Quattrone, Diego [0000-0002-6051-8309], Bobes, Julio [0000-0003-2187-4033], Bernardo, Miguel [0000-0001-8748-6717], Menezes, Paulo Rossi [0000-0001-6330-3314], Kirkbride, James B [0000-0003-3401-0824], Murray, Robin M [0000-0003-0829-0519], Apollo - University of Cambridge Repository, Psychiatrie & Neuropsychologie, MUMC+: MA Psychiatrie (3), RS: MHeNs - R3 - Neuroscience, RS: MHeNs - R2 - Mental Health, MUMC+: Hersen en Zenuw Centrum (3), APH - Mental Health, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, and Adult Psychiatry
- Subjects
ESTUDO DE CASO ,STRESS ,CHILDHOOD ,lcsh:Medicine ,childhood adversities ,psychosi ,Parental Death ,0302 clinical medicine ,Psicosi en els infants ,Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat ,Medicine ,early parental death ,psychosis ,Dol ,RACE ,General Medicine ,Infants Salut mental ,childhood adversitie ,Esquizofrènia ,Maternal death ,HEALTH ,case-control ,early bereavement ,DISORDERS ,Offspring ,DISADVANTAGE ,ethnic minorities ,ethnic minoritie ,Article ,Odds ,03 medical and health sciences ,BEREAVEMENT ,Journal Article ,Mortalitat ,Psiquiatria ,Mortality ,Risk factor ,Settore MED/25 - Psichiatria ,METAANALYSIS ,multi-country ,business.industry ,MORTALITY ,lcsh:R ,Case-control study ,Odds ratio ,medicine.disease ,Confidence interval ,030227 psychiatry ,population-based ,schizophrenia ,Psychoses in children ,business ,030217 neurology & neurosurgery ,Bereavement ,Demography - Abstract
Evidence for early parental death as a risk factor for psychosis in offspring is inconclusive. We analyzed data from a six-country, case-control study to examine the associations of early parental death, type of death (maternal, paternal, both), and child’s age at death with psychosis, both overall and by ethnic group. In fully adjusted multivariable mixed-effects logistic regression models, experiencing early parental death was associated with 1.54-fold greater odds of psychosis (95% confidence interval (CI): 1.23, 1.92). Experiencing maternal death had 2.27-fold greater odds (95% CI: 1.18, 4.37), paternal death had 1.14-fold greater odds (95% CI: 0.79, 1.64), and both deaths had 4.42-fold greater odds (95% CI: 2.57, 7.60) of psychosis compared with no early parental death. Experiencing parental death between 11 and 16 years of age had 2.03-fold greater odds of psychosis than experiencing it before five years of age (95% CI: 1.02, 4.04). In stratified analyses, experiencing the death of both parents had 9.22-fold greater odds of psychosis among minority ethnic groups (95% CI: 2.02−28.02) and no elevated odds among the ethnic majority (odds ratio (OR): 0.96; 95% CI: 0.10−8.97), which could be due in part to the higher prevalence of early parental death among minority ethnic groups but should be interpreted cautiously given the wide confidence intervals.
- Published
- 2019
- Full Text
- View/download PDF
67. Suicide mortality in Spain and its relationship with economic indicators in a region with high suicide rates.
- Author
-
Fernández Navarro, P., López-Cuadrado, T., Barrigón, M.L., López-Castroman, J., Sanchez-Alonso, M., Arrojo, M., Baca-García, E., and Fernández-Cuenca, R.
- Subjects
- *
SUICIDAL behavior , *MORTALITY , *ECONOMIC indicators , *UNEMPLOYMENT , *RECESSIONS - Abstract
Introduction Spatial patterns of mortality could help us to focus research to achieve prevention. On the other hand, recent research has shown an association between unemployment and suicide, but the mediating factors in this relationship are still unknown. Objectives We investigated the provincial spatial patterns of suicide mortality in Spain, and the effect of unemployment and economic recession on suicide mortality rates in the Spanish region of Galicia that has high suicide rates. Method To describe regional suicide mortality in Spain and to assess its association with recession and unemployment in Galicia, we calculated age-standardized suicide rates in men and women throughout 1975–2012 by region and performed a time-trend Generalized Additive Model using mortality data provided by National Statistics Institute and employment data collected from Statistics Institute of Galicia. Results In Spain, during the study period, there were 105,134 suicides with an age-adjusted rate of 10.2 and 3.02 per 100,000 population in men and women, respectively. There is a high variability in mortality rates across Spanish provinces. Madrid had the lower rates and Asturias and Galicia the higher ones. In Galicia, suicide rates were 13.7 in men and 4.3 in women per 100,000 and we found that economic recession and unemployment interacted with regards to suicide rates ( P = 9.80E-4) and after stratifying by sex, the effect was confirmed only among men ( P = 8.70E-3). Conclusions In Spain, suicide mortality varies greatly by region and in Galicia that is one of Spanish regions with higher suicide rates, unemployment was related with suicide during economic recession periods. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
68. Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factors.
- Author
-
Ferraro L, Di Forti M, La Barbera D, La Cascia C, Morgan C, Tripoli G, Jongsma H, Seminerio F, Sartorio C, Sideli L, Tarricone I, Carloni AL, Szoke A, Pignon B, Bernardo M, de Haan L, Arango C, Velthorst E, Gayer-Anderson C, Kirkbride J, Rutten BPF, Lasalvia A, Tosato S, Del Ben CM, Menezes PR, Bobes J, Arrojo M, Tortelli A, Jones P, Selten JP, van Os J, Murray R, Quattrone D, and Vassos E
- Subjects
- Humans, Male, Female, Risk Factors, Adult, Young Adult, Cognitive Dysfunction etiology, Adolescent, Adverse Childhood Experiences statistics & numerical data, Cognition, Minority Groups statistics & numerical data, Minority Groups psychology, Case-Control Studies, Psychotic Disorders etiology, Psychotic Disorders epidemiology
- Abstract
Background: Previous studies identified clusters of first-episode psychosis (FEP) patients based on cognition and premorbid adjustment. This study examined a range of socio-environmental risk factors associated with clusters of FEP, aiming a) to compare clusters of FEP and community controls using the Maudsley Environmental Risk Score for psychosis (ERS), a weighted sum of the following risks: paternal age, childhood adversities, cannabis use, and ethnic minority membership; b) to explore the putative differences in specific environmental risk factors in distinguishing within patient clusters and from controls., Methods: A univariable general linear model (GLS) compared the ERS between 1,263 community controls and clusters derived from 802 FEP patients, namely, low (n = 223) and high-cognitive-functioning (n = 205), intermediate (n = 224) and deteriorating (n = 150), from the EU-GEI study. A multivariable GLS compared clusters and controls by different exposures included in the ERS., Results: The ERS was higher in all clusters compared to controls, mostly in the deteriorating ( β =2.8, 95% CI 2.3 3.4
, η2 = 0.049) and the low-cognitive-functioning cluster ( β =2.4, 95% CI 1.9 2.8, η2 = 0.049) and distinguished them from the cluster with high-cognitive-functioning. The deteriorating cluster had higher cannabis exposure (meandifference = 0.48, 95% CI 0.49 0.91) than the intermediate having identical IQ, and more people from an ethnic minority (meandifference = 0.77, 95% CI 0.24 1.29) compared to the high-cognitive-functioning cluster., Conclusions: High exposure to environmental risk factors might result in cognitive impairment and lower-than-expected functioning in individuals at the onset of psychosis. Some patients' trajectories involved risk factors that could be modified by tailored interventions.- Published
- 2025
- Full Text
- View/download PDF
69. Identification of gene co-expression modules from zebrafish brain data: Applications in psychiatry illustrated through alcohol-related traits.
- Author
-
Al-Soufi L, Arana ÁJ, Facal F, Flórez G, Vázquez FL, Arrojo M, Sánchez L, and Costas J
- Subjects
- Animals, Humans, Multifactorial Inheritance, Disease Models, Animal, Gene Expression genetics, Zebrafish, Brain metabolism, Alcoholism genetics, Gene Regulatory Networks, Genome-Wide Association Study
- Abstract
Cumulative evidence suggests that zebrafish is a useful model in psychiatric research. Weighted Gene Co-expression Network Analysis (WGCNA) enables the reduction of genome-wide expression data to modules of highly co-expressed genes, which are hypothesized to interact within molecular networks. In this study, we first applied WGCNA to zebrafish brain expression data across different experimental conditions. Then, we characterized the different co-expression modules by gene-set enrichment analysis and hub gene-phenotype association. Finally, we analyzed association of polygenic risk scores (PRSs) based on genes of some interesting co-expression modules with alcohol dependence in 524 patients and 729 controls from Galicia, using competitive tests. Our approach revealed 34 co-expression modules in the zebrafish brain, with some showing enrichment in human synaptic genes, brain tissues, or brain developmental stages. Moreover, certain co-expression modules were enriched in psychiatry-related GWAS and comprised hub genes associated with psychiatry-related traits in both human GWAS and zebrafish models. Expression patterns of some co-expression modules were associated with the tested experimental conditions, mainly with substance withdrawal and cold stress. Notably, a PRS based on genes from co-expression modules exclusively associated with substance withdrawal in zebrafish showed a stronger association with human alcohol dependence than PRSs based on randomly selected brain-expressed genes. In conclusion, our analysis led to the identification of co-expressed gene modules that may model human brain gene networks involved in psychiatry-related traits. Specifically, we detected a cluster of co-expressed genes whose expression was exclusively associated with substance withdrawal in zebrafish, which significantly contributed to alcohol dependence susceptibility in humans., Competing Interests: Declaration of competing interest None., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
70. Polygenic and Polyenvironment Interplay in Schizophrenia-Spectrum Disorder and Affective Psychosis; the EUGEI First Episode Study.
- Author
-
Rodriguez V, Alameda L, Aas M, Gayer-Anderson C, Trotta G, Spinazzola E, Quattrone D, Tripoli G, Jongsma HE, Stilo S, La Cascia C, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Tarricone I, Bonora E, Jamain S, Selten JP, Velthorst E, de Haan L, Llorca PM, Arrojo M, Bobes J, Bernardo M, Arango C, Kirkbride J, Jones PB, Rutten BP, Richards A, Sham PC, O'Donovan M, Van Os J, Morgan C, Di Forti M, Murray RM, and Vassos E
- Abstract
Background: Multiple genetic and environmental risk factors play a role in the development of both schizophrenia-spectrum disorders and affective psychoses. How they act in combination is yet to be clarified., Methods: We analyzed 573 first episode psychosis cases and 1005 controls, of European ancestry. Firstly, we tested whether the association of polygenic risk scores for schizophrenia, bipolar disorder, and depression (PRS-SZ, PRS-BD, and PRS-D) with schizophrenia-spectrum disorder and affective psychosis differed when participants were stratified by exposure to specific environmental factors. Secondly, regression models including each PRS and polyenvironmental measures, including migration, paternal age, childhood adversity and frequent cannabis use, were run to test potential polygenic by polyenvironment interactions., Results: In schizophrenia-spectrum disorder vs controls comparison, PRS-SZ was the strongest genetic predictor, having a nominally larger effect in nonexposed to strong environmental factors such as frequent cannabis use (unexposed vs exposed OR 2.43 and 1.35, respectively) and childhood adversity (3.04 vs 1.74). In affective psychosis vs controls, the relative contribution of PRS-D appeared to be stronger in those exposed to environmental risk. No evidence of interaction was found between any PRS with polyenvironmental score., Conclusions: Our study supports an independent role of genetic liability and polyenvironmental risk for psychosis, consistent with the liability threshold model. Whereas schizophrenia-spectrum disorders seem to be mostly associated with polygenic risk for schizophrenia, having an additive effect with well-replicated environmental factors, affective psychosis seems to be a product of cumulative environmental insults alongside a higher genetic liability for affective disorders., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.)
- Published
- 2024
- Full Text
- View/download PDF
71. The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.
- Author
-
Austin-Zimmerman I, Spinazzola E, Quattrone D, Wu-Choi B, Trotta G, Li Z, Johnson E, Richards AL, Freeman TP, Tripoli G, Gayer-Anderson C, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, Tosato S, Tarricone I, Berardi D, Bonora E, Seri M, D'Andrea G, Szöke A, Arango C, Bobes J, Sanjuán J, Santos JL, Arrojo M, Velthorst E, Bernardo M, Del-Ben CM, Rossi Menezes P, Selten JP, Jones PB, Kirkbride JB, Rutten BPF, Tortelli A, Llorca PM, de Haan L, Stilo S, La Barbera D, Lasalvia A, Schurnhoff F, Pignon B, van Os J, Lynskey M, Morgan C, O' Donovan M, Lewis CM, Sham PC, Murray RM, Vassos E, and Di Forti M
- Abstract
Background: The association between cannabis and psychosis is established, but the role of underlying genetics is unclear. We used data from the EU-GEI case-control study and UK Biobank to examine the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS) on risk for psychosis., Methods: Genome-wide association study summary statistics from the Psychiatric Genomics Consortium and the Genomic Psychiatry Cohort were used to calculate schizophrenia and cannabis use disorder (CUD) PRS for 1098 participants from the EU-GEI study and 143600 from the UK Biobank. Both datasets had information on cannabis use., Results: In both samples, schizophrenia PRS and cannabis use independently increased risk of psychosis. Schizophrenia PRS was not associated with patterns of cannabis use in the EU-GEI cases or controls or UK Biobank cases. It was associated with lifetime and daily cannabis use among UK Biobank participants without psychosis, but the effect was substantially reduced when CUD PRS was included in the model. In the EU-GEI sample, regular users of high-potency cannabis had the highest odds of being a case independently of schizophrenia PRS (OR daily use high-potency cannabis adjusted for PRS = 5.09, 95% CI 3.08-8.43, p = 3.21 × 10
-10 ). We found no evidence of interaction between schizophrenia PRS and patterns of cannabis use., Conclusions: Regular use of high-potency cannabis remains a strong predictor of psychotic disorder independently of schizophrenia PRS, which does not seem to be associated with heavy cannabis use. These are important findings at a time of increasing use and potency of cannabis worldwide.- Published
- 2024
- Full Text
- View/download PDF
72. Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.
- Author
-
Roldan L, Sánchez-Gutiérrez T, Fernández-Arias I, Rodríguez-Toscano E, López G, Merchán-Naranjo J, Calvo A, Rapado-Castro M, Parellada M, Moreno C, Ferraro L, La Barbera D, La Cascia C, Tripoli G, Di Forti M, Murray RM, Quattrone D, Morgan C, Gayer-Anderson C, Jones PB, Jongsma HE, Kirkbride JB, van Os J, García-Portilla P, Al-Halabí S, Bobes J, de Haan L, Bernardo M, Santos JL, Sanjuán J, Arrojo M, Szoke A, Rutten BP, Stilo SA, Tarricone I, Lasalvia A, Tosato S, Llorca PM, Menezes PR, Selten JP, Tortelli A, Velthorst E, Del-Ben CM, Arango C, and Díaz-Caneja CM
- Abstract
Background: Cannabis use and familial vulnerability to psychosis have been associated with social cognition deficits. This study examined the potential relationship between cannabis use and cognitive biases underlying social cognition and functioning in patients with first episode psychosis (FEP), their siblings, and controls., Methods: We analyzed a sample of 543 participants with FEP, 203 siblings, and 1168 controls from the EU-GEI study using a correlational design. We used logistic regression analyses to examine the influence of clinical group, lifetime cannabis use frequency, and potency of cannabis use on cognitive biases, accounting for demographic and cognitive variables., Results: FEP patients showed increased odds of facial recognition processing (FRP) deficits (OR = 1.642, CI 1.123-2.402) relative to controls but not of speech illusions (SI) or jumping to conclusions (JTC) bias, with no statistically significant differences relative to siblings. Daily and occasional lifetime cannabis use were associated with decreased odds of SI (OR = 0.605, CI 0.368-0.997 and OR = 0.646, CI 0.457-0.913 respectively) and JTC bias (OR = 0.625, CI 0.422-0.925 and OR = 0.602, CI 0.460-0.787 respectively) compared with lifetime abstinence, but not with FRP deficits, in the whole sample. Within the cannabis user group, low-potency cannabis use was associated with increased odds of SI (OR = 1.829, CI 1.297-2.578, FRP deficits (OR = 1.393, CI 1.031-1.882, and JTC (OR = 1.661, CI 1.271-2.171) relative to high-potency cannabis use, with comparable effects in the three clinical groups., Conclusions: Our findings suggest increased odds of cognitive biases in FEP patients who have never used cannabis and in low-potency users. Future studies should elucidate this association and its potential implications.
- Published
- 2024
- Full Text
- View/download PDF
73. Prediction of pharmacological response in OCD using machine learning techniques and clinical and neuropsychological variables.
- Author
-
Tubío-Fungueiriño M, Cernadas E, Fernández-Delgado M, Arrojo M, Bertolin S, Real E, Menchon JM, Carracedo A, Alonso P, Fernández-Prieto M, and Segalàs C
- Abstract
Introduction: Obsessive compulsive disorder is associated with affected executive functioning, including memory, cognitive flexibility, and organizational strategies. As it was reported in previous studies, patients with preserved executive functions respond better to pharmacological treatment, while others need to keep trying different pharmacological strategies., Material and Methods: In this work we used machine learning techniques to predict pharmacological response (OCD patients' symptomatology reduction) based on executive functioning and clinical variables. Among those variables we used anxiety, depression and obsessive-compulsive symptoms scores by applying State-Trait Anxiety Inventory, Hamilton Depression Rating Scale and Yale-Brown Obsessive Compulsive Scale respectively, while Rey-Osterrieth Complex Figure Test was used to assess organisation skills and non-verbal memory; Digits' subtests from Wechsler Adult Intelligence Scale-IV were used to assess short-term memory and working memory; and Raven's Progressive Matrices were applied to assess problem solving and abstract reasoning., Results: As a result of our analyses, we created a reliable algorithm that predicts Y-BOCS score after 12 weeks based on patients' clinical characteristics (sex at birth, age, pharmacological strategy, depressive and obsessive-compulsive symptoms, years passed since diagnostic and Raven's Progressive Matrices score) and Digits' scores. A high correlation (0.846) was achieved in predicted and true values., Conclusions: The present study proves the viability to predict if a patient would respond or not to a certain pharmacological strategy with high reliability based on sociodemographics, clinical variables and cognitive functions as short-term memory and working memory. These results are promising to develop future prediction models to help clinical decision making., (Copyright © 2024 The Authors. Published by Elsevier España S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
74. Variation of subclinical psychosis as a function of population density across different European settings: Findings from the multi-national EU-GEI study.
- Author
-
D'Andrea G, Quattrone D, Tripoli G, Spinazzola E, Gayer-Anderson C, Jongsma HE, Sideli L, Stilo SA, La Cascia C, Ferraro L, La Barbera D, Tortelli A, Velthorst E, de Haan L, Llorca PM, Santos JL, Arrojo M, Bobes J, Sanjuán J, Bernardo M, Arango C, Kirkbride JB, Jones PB, Rutten BP, Schürhoff F, Szöke A, van Os J, Vassos E, Selten JP, Morgan C, Di Forti M, Tarricone I, and Murray RM
- Abstract
Background: Urbanicity is a well-established risk factor for psychosis. Our recent multi-national study found an association between urbanicity and clinical psychosis in Northern Europe but not in Southern Europe. In this study, we hypothesized that the effect of current urbanicity on variation of schizotypy would be greater in North-western Europe countries than in Southern Europe ones., Methods: We recruited 1080 individuals representative of the populations aged 18-64 of 14 different sites within 5 countries, classified as either North-western Europe (England, France, and The Netherlands) with Southern Europe (Spain and Italy). Our main outcome was schizotypy, assessed through the Structured Interview for Schizotypy-Revised. Our main exposure was current urbanicity, operationalized as local population density. A priori confounders were age, sex, ethnic minority status, childhood maltreatment, and social capital. Schizotypy variation was assessed using multi-level regression analysis. To test the differential effect of urbanicity between North-western and Southern European, we added an interaction term between population density and region of recruitment., Results: Population density was associated with schizotypy (β = 0.248,95%CI = 0.122-0.375;p < 0.001). The addition of the interaction term improved the model fit (likelihood test ratio:χ
2 = 6.85; p = 0.009). The effect of urbanicity on schizotypy was substantially stronger in North-western Europe (β = 0.620,95%CI = 0.362-0.877;p < 0.001) compared with Southern Europe (β = 0.190,95%CI = 0.083-0.297;p = 0.001)., Conclusions: The association between urbanicity and both subclinical schizotypy and clinical psychosis, rather than being universal, is context-specific. Considering that urbanization is a rapid and global process, further research is needed to disentangle the specific factors underlying this relationship., (© 2024 The Author(s). Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
75. The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis.
- Author
-
Alameda L, Rodriguez V, Di Forti M, Spinazzola E, Trotta G, Arango C, Arrojo M, Bernardo M, Bobes J, de Haan L, Del-Ben CM, Gayer-Anderson C, Sideli L, Jones PB, Kirkbride JB, La Cascia C, Tripoli G, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Llorca PM, Menezes PR, van Os J, Rutten BP, Santos JL, Sanjuán J, Selten JP, Szöke A, Tarricone I, Tortelli A, Velthorst E, Jongsma HE, Vassos E, Quattrone D, Murray RM, and Aas M
- Subjects
- Humans, Female, Male, Adult, Case-Control Studies, Young Adult, Gene-Environment Interaction, Adolescent, Risk Factors, Middle Aged, Genetic Risk Score, Multifactorial Inheritance, Psychotic Disorders genetics, Psychotic Disorders psychology, Adverse Childhood Experiences psychology, Bipolar Disorder genetics, Bipolar Disorder psychology, Depressive Disorder, Major genetics, Schizophrenia genetics, Genetic Predisposition to Disease
- Abstract
Childhood adversity is associated with various clinical dimensions in psychosis; however, how genetic vulnerability shapes the adversity-associated psychopathological signature is yet to be studied. We studied data of 583 First Episode Psychosis (FEP) cases from the EU-GEI FEP case-control study, including Polygenic risk scores for major depressive disorder (MDD-PRS), bipolar disorder (BD-PRS) and schizophrenia (SZ-PRS); childhood adversity measured with the total score of the Childhood Trauma Questionnaire (CTQ); and positive, negative, depressive and manic psychopathological domains from a factor model of transdiagnostic dimensions. Genes and environment interactions were explored as a departure from a multiplicative effect of PRSs and total CTQ on each dimension. Analyses were adjusted for age, sex, 10 PCA, site of recruitment and for medication. A childhood adversity and PRS multiplicative interaction was observed between A) the CTQ and MDD-PRS on the predominance of positive (β = 0.42, 95% CI = [0.155, 0.682], p = 0.004); and depressive (β = 0.33, 95% CI = [0.071, 0.591], p = 0.013) dimensions; B) between the CTQ and BD-PRS on the positive dimension (β = 0.45, 95% CI = [0.106, 0.798], p = 0.010), and C) with the CTQ and SZ-PRS on the positive dimension (β = -0.34, 95% CI = [-0.660, -0.015], p = 0.040). Bonferroni corrected p-value of significance was set at 0.0125. In conclusion, despite being underpowered, this study suggests that genetic liability for MDD and BD may have a moderating effect on the sensibility of childhood adversity on depressive and positive psychotic dimensions. This supports the hypothesis of an affective pathway to psychosis in those exposed to childhood adversity., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
76. Methylomic signature of current cannabis use in two first-episode psychosis cohorts.
- Author
-
Dempster EL, Wong CCY, Burrage J, Hannon E, Quattrone D, Trotta G, Rodriguez V, Alameda L, Spinazzola E, Tripoli G, Austin-Zimmerman I, Li Z, Gayer-Anderson C, Freeman TP, Johnson EC, Jongsma HE, Stilo S, La Cascia C, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Tarricone I, D'Andrea G, Galatolo M, Tortelli A, Pompili M, Selten JP, de Haan L, Menezes PR, Del Ben CM, Santos JL, Arrojo M, Bobes J, Sanjuán J, Bernardo M, Arango C, Jones PB, Breen G, Mondelli V, Dazzan P, Iyegbe C, Vassos E, Morgan C, Mukherjee D, van Os J, Rutten B, O'Donovan MC, Sham P, Mill J, Murray R, and Di Forti M
- Abstract
The rising prevalence and legalisation of cannabis worldwide have underscored the need for a comprehensive understanding of its biological impact, particularly on mental health. Epigenetic mechanisms, specifically DNA methylation, have gained increasing recognition as vital factors in the interplay between risk factors and mental health. This study aimed to explore the effects of current cannabis use and high-potency cannabis on DNA methylation in two independent cohorts of individuals experiencing first-episode psychosis (FEP) compared to control subjects. The combined sample consisted of 682 participants (188 current cannabis users and 494 never users). DNA methylation profiles were generated on blood-derived DNA samples using the Illumina DNA methylation array platform. A meta-analysis across cohorts identified one CpG site (cg11669285) in the CAVIN1 gene that showed differential methylation with current cannabis use, surpassing the array-wide significance threshold, and independent of the tobacco-related epigenetic signature. Furthermore, a CpG site localised in the MCU gene (cg11669285) achieved array-wide significance in an analysis of the effect of high-potency (THC = > 10%) current cannabis use. Pathway and regional analyses identified cannabis-related epigenetic variation proximal to genes linked to immune and mitochondrial function, both of which are known to be influenced by cannabinoids. Interestingly, a model including an interaction term between cannabis use and FEP status identified two sites that were significantly associated with current cannabis use with a nominally significant interaction suggesting that FEP status might moderate how cannabis use affects DNA methylation. Overall, these findings contribute to our understanding of the epigenetic impact of current cannabis use and highlight potential molecular pathways affected by cannabis exposure., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
77. Spanish validation of the Empirically Developed Clinical Staging Model (EmDe-5) for patients with bipolar disorder.
- Author
-
de la Fuente-Tomás L, Arranz B, Sierra P, Sánchez-Autet M, García-Blanco A, Gutiérrez-Rojas L, Balanzá-Martínez V, Vidal-Rubio S, Vieta E, Jiménez E, Hernández C, Arrojo M, Gómez-Trigo J, Zapico-Merayo Y, Pelayo-Terán JM, Pérez-Solà V, Mur E, Cardoner N, González-Pinto A, Zorrilla I, Ruiz-Veguilla M, Catalán-Barragán R, Safont G, Martínez-Cao C, Sáiz P, Bobes J, and García-Portilla MP
- Subjects
- Humans, Female, Male, Spain epidemiology, Adult, Middle Aged, Severity of Illness Index, Disease Progression, Suicide, Attempted statistics & numerical data, Reproducibility of Results, Comorbidity, Bipolar Disorder epidemiology, Bipolar Disorder pathology
- Abstract
Introduction: Bipolar disorder (BD) has been reconceptualised as a progressive disorder that develops from mild to severe presentations. An empirical staging model - the Empirically Developed Clinical Staging Model for BD (EmDe-5) - was developed in a previous study. This study aims to further validate that model using a larger and more representative Spanish sample., Material and Methods: 183 BD outpatients were recruited at 11 sites in Spain. Assessment included clinical characteristics of the BD (number of hospitalisations, number of suicide attempts, comorbid personality disorders), physical health (BMI, metabolic syndrome, number of physical illnesses), cognition (SCIP), functioning (permanently disabled due to BD, FAST), and quality of life (SF-36). The CGI-S, VAS-S, and psychopharmacological treatment pattern were used as external validators., Results: Ten patients (51.5%) were classified as stage 1, 33 (18%) as stage 2, 93 (508%) as stage 3, 37 (202%) as stage 4, and 10 (55%) as stage 5. All profilers, other than number of suicide attempts (p=0.311) and comorbid personality disorder (p=0.061), exhibited worse scores from stage 1 to 5. As expected, VAS-S and CGI-S scores were worse in the later stages. Regarding treatment, early stages (1-2) were associated with the use of one to three drugs while late stages (4-5) were associated with four or more drugs (p=0.002)., Conclusions: We confirm the EmDe-5 staging model's construct validity. The ease of obtaining the profilers, together with the operational criteria provided to quantify them, will facilitate the use of the EmDe-5 staging model in daily clinical practice., (Copyright © 2021. Published by Elsevier España S.L.U.)
- Published
- 2024
- Full Text
- View/download PDF
78. Meta-analysis of the effects of adjuvant drugs in co-occurring bipolar and substance use disorder.
- Author
-
Radua J, Fortea L, Goikolea JM, Zorrilla I, Bernardo M, Arrojo M, Cunill R, Castells X, Becoña E, López-Durán A, Torrens M, Tirado-Muñoz J, Fonseca F, Arranz B, Garriga M, Sáiz PA, Flórez G, San L, and González-Pinto A
- Subjects
- Humans, Comorbidity, Diagnosis, Dual (Psychiatry), Randomized Controlled Trials as Topic, Bipolar Disorder drug therapy, Bipolar Disorder epidemiology, Substance-Related Disorders drug therapy, Substance-Related Disorders epidemiology
- Abstract
Background: Individuals with bipolar disorder (BD) often have co-occurring substance use disorders (SUDs), which substantially impoverish the course of illness. Despite the importance of this dual diagnosis, the evidence of the efficacy and safety of adjuvant treatments is mostly unknown., Objective: To perform a meta-analysis to evaluate the efficacy and safety of adjuvant drugs in patients with co-occurring BD and SUD., Methods: We searched PubMed, Scopus, and Web of Knowledge until 30th April 2022 for randomized clinical trials (RCT) evaluating the efficacy and safety of adjuvant drugs compared to placebo in patients with a dual diagnosis of BD and SUD. We meta-analyzed the effect of adjuvant drugs on general outcomes (illness severity, mania, depression, anxiety, abstinence, substance craving, substance use, gamma-GT, adherence, and adverse events) and used the results to objectively assess the quality of the evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. For completeness, we also report the specific effects of specific adjuvant drugs in patients with specific substance disorders., Results: We included 15 RCT studies (9 alcohol, 3 cocaine, 2 nicotine, and 1 cannabis) comprising 628 patients allocated to treatment and 622 to placebo. There was low-quality evidence that adjuvant drugs may reduce illness severity (g=-0.25, 95% CI: -0.44, -0.06), and very-low quality evidence that they may decrease substance use (g=-0.23, 95% CI: -0.44, -0.02) and increase substance abstinence (g=0.21, 95% CI: 0.04, 0.38)., Discussion: There is low-quality evidence that adjuvant drugs may help reduce illness severity, probably via facilitating abstinence and lower substance use. However, the evidence is weak; thus, these results should be considered cautiously until better evidence exists., (Copyright © 2023 SEP y SEPB. Published by Elsevier España S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
79. Association between psychiatric admissions in patients with schizophrenia and IL-6 plasma levels polygenic score.
- Author
-
Facal F, Arrojo M, Páramo M, and Costas J
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Schizophrenia blood, Interleukin-6 blood, Multifactorial Inheritance
- Abstract
Schizophrenia diagnosis and admission history were associated with a polygenic score (PGS) for schizophrenia based on a subset of variants that act by modifying the expression of genes whose expression is also modified by antipsychotics. This gene set was enriched in cytokine production. Interleukin-6 (IL-6) is the only cytokine whose plasma levels were associated both with schizophrenia diagnosis and with acute decompensations in the largest meta-analysis. Therefore, we hypothesized that an IL-6 PGS, but not other cytokines PGSs, would be associated with schizophrenia chronicity/psychiatric admissions. Using the IL-6 PGS model from The PGS Catalog, IL-6 PGS was calculated in 427 patients with schizophrenia and data regarding admission history. Association between IL-6 PGS and chronicity, measured as number and duration of psychiatric admissions, or ever readmission was analyzed by multivariate ordinal and logistic regression, respectively. Specificity of results was assessed by analysis of PGSs from the other cytokines at The PGS Catalog with meta-analytic evidence of association with schizophrenia diagnosis or acute decompensations, IL-1RA, IL-4, IL-8, and IL-12. IL-6 PGS was associated with schizophrenia chronicity, explaining 1.51% of variability (OR = 1.29, 95% CI 1.07-1.55, P = 0.007). There was no association with ever readmission. Other cytokines PGSs were not associated with chronicity. Association with IL-6 PGS was independent of association with schizophrenia PGS. Our results provide evidence that genetically regulated higher levels of IL-6 are involved in schizophrenia chronicity, highlighting the relevance of immunity processes for a subgroup of patients., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2024
- Full Text
- View/download PDF
80. Brief psychological intervention for suicide prevention based on problem-solving applied in different formats to people over 50 years old: protocol for a randomized controlled trial.
- Author
-
Vázquez FL, Torres ÁJ, Blanco V, Bouza Q, Otero P, Andrade E, Simón MÁ, Bueno AM, Arrojo M, Páramo M, and Fernández A
- Subjects
- Humans, Middle Aged, Male, Female, Suicidal Ideation, Psychosocial Intervention methods, Psychotherapy, Brief methods, Aged, Mobile Applications, Problem Solving, Suicide Prevention
- Abstract
Background: Suicide is a major public health problem, especially among individuals over 50 years old. Despite the suitability of this life stage for prevention, research on the efficacy of psychological interventions is scarce and methodologically limited, affecting their clinical utility and efficacy. Brief, flexible interventions that can be applied both in-person and remotely are needed. This study aims to evaluate the efficacy of a brief problem-solving-based suicide prevention program applied through various modalities to individuals over 50 years old., Methods: A randomized controlled trial will be conducted. A sample of 212 adults aged 50 or older with suicidal ideation will be randomly assigned to a problem-solving-based psychological intervention administered face-to-face (PSPI-P; n = 53), by telephone multiconference (PSPI-M; n = 53), via a smartphone app (PSPI-A; n = 53), or to a usual care control group (UCCG; n = 53). The intervention will be delivered in 7 sessions or modules of 90 min each. Blind trained evaluators will conduct assessments at pre-intervention, post-intervention, and follow-ups at 3, 6, and 12 months. The primary outcome will be suicidal ideation evaluated using the Suicidal Ideation Scale (SSI) and the Columbia Suicide Severity Rating Scale (C-SSRS). Secondary outcomes will include hopelessness, anxiety and depression symptoms, reasons for living, impulsivity, problem-solving skills, social support, anger syndrome, gratitude, personality, dropouts, treatment adherence, and satisfaction with the intervention., Discussion: This study will provide evidence of the efficacy of a brief problem-solving-based intervention for suicide prevention in individuals over 50 years old, administered face-to-face, by telephone multiconference, and via a smartphone app. If results are favorable, it will indicate that an effective, accessible, clinically and socially useful suicide prevention intervention has been developed for affected individuals, families, and communities., Trial Registration: ClinicalTrials.gov NCT06338904. Registered April 1, 2024., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
81. Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders.
- Author
-
González-Peñas J, Alloza C, Brouwer R, Díaz-Caneja CM, Costas J, González-Lois N, Gallego AG, de Hoyos L, Gurriarán X, Andreu-Bernabeu Á, Romero-García R, Fañanás L, Bobes J, González-Pinto A, Crespo-Facorro B, Martorell L, Arrojo M, Vilella E, Gutiérrez-Zotes A, Perez-Rando M, Moltó MD, Buimer E, van Haren N, Cahn W, O'Donovan M, Kahn RS, Arango C, Pol HH, Janssen J, and Schnack H
- Subjects
- Humans, Adult, Middle Aged, Male, Female, Adolescent, Young Adult, Aged, Cerebral Cortical Thinning genetics, Cerebral Cortical Thinning diagnostic imaging, Cerebral Cortical Thinning pathology, Magnetic Resonance Imaging, Longitudinal Studies, Cerebral Cortex diagnostic imaging, Cerebral Cortex pathology, Genetic Predisposition to Disease genetics, Schizophrenia genetics, Schizophrenia pathology, Schizophrenia diagnostic imaging, Neurodevelopmental Disorders genetics, Neurodevelopmental Disorders pathology, Neurodevelopmental Disorders diagnostic imaging
- Abstract
Background: Schizophrenia is a highly heritable disorder characterized by increased cortical thinning throughout the life span. Studies have reported a shared genetic basis between schizophrenia and cortical thickness. However, no genes whose expression is related to abnormal cortical thinning in schizophrenia have been identified., Methods: We conducted linear mixed models to estimate the rates of accelerated cortical thinning across 68 regions from the Desikan-Killiany atlas in individuals with schizophrenia compared with healthy control participants from a large longitudinal sample (n
cases = 169 and ncontrols = 298, ages 16-70 years). We studied the correlation between gene expression data from the Allen Human Brain Atlas and accelerated thinning estimates across cortical regions. Finally, we explored the functional and genetic underpinnings of the genes that contribute most to accelerated thinning., Results: We found a global pattern of accelerated cortical thinning in individuals with schizophrenia compared with healthy control participants. Genes underexpressed in cortical regions that exhibit this accelerated thinning were downregulated in several psychiatric disorders and were enriched for both common and rare disrupting variation for schizophrenia and neurodevelopmental disorders. In contrast, none of these enrichments were observed for baseline cross-sectional cortical thickness differences., Conclusions: Our findings suggest that accelerated cortical thinning, rather than cortical thickness alone, serves as an informative phenotype for neurodevelopmental disruptions in schizophrenia. We highlight the genetic and transcriptomic correlates of this accelerated cortical thinning, emphasizing the need for future longitudinal studies to elucidate the role of genetic variation and the temporal-spatial dynamics of gene expression in brain development and aging in schizophrenia., (Copyright © 2024 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
82. The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.
- Author
-
Brink V, Andleeb H, Gayer-Anderson C, Arango C, Arrojo M, Berardi D, Bernardo M, Bobes J, Del-Ben CM, Ferraro L, de Haan L, La Barbera D, La Cascia C, Lasalvia A, Llorca PM, Menezes PR, Pignon B, Sanjuán J, Santos JL, Selten JP, Tarricone I, Tortelli A, Tripoli G, Velthorst E, Rutten BPF, van Os J, Quattrone D, Murray RM, Jones PB, Morgan C, Di Forti M, Jongsma HE, and Kirkbride JB
- Subjects
- Humans, Adult, Male, Female, Incidence, Young Adult, Adolescent, Middle Aged, Europe epidemiology, Psychosocial Deprivation, Marijuana Use epidemiology, Psychotic Disorders epidemiology
- Abstract
Background and Hypothesis: Recent findings suggest the incidence of first-episode psychotic disorders (FEP) varies according to setting-level deprivation and cannabis use, but these factors have not been investigated together. We hypothesized deprivation would be more strongly associated with variation in FEP incidence than the prevalence of daily or high-potency cannabis use between settings., Study Design: We used incidence data in people aged 18-64 years from 14 settings of the EU-GEI study. We estimated the prevalence of daily and high-potency cannabis use in controls as a proxy for usage in the population at-risk; multiple imputations by chained equations and poststratification weighting handled missing data and control representativeness, respectively. We modeled FEP incidence in random intercepts negative binomial regression models to investigate associations with the prevalence of cannabis use in controls, unemployment, and owner-occupancy in each setting, controlling for population density, age, sex, and migrant/ethnic group., Study Results: Lower owner-occupancy was independently associated with increased FEP (adjusted incidence rate ratio [aIRR]: 0.76, 95% CI: 0.61-0.95) and non-affective psychosis incidence (aIRR: 0.68, 95% CI: 0.55-0.83), after multivariable adjustment. Prevalence of daily cannabis use in controls was associated with the incidence of affective psychoses (aIRR: 1.53, 95% CI: 1.02-2.31). We found no association between FEP incidence and unemployment or high-potency cannabis use prevalence. Sensitivity analyses supported these findings., Conclusions: Lower setting-level owner-occupancy and increased prevalence of daily cannabis use in controls independently contributed to setting-level variance in the incidence of different psychotic disorders. Public health interventions that reduce exposure to these harmful environmental factors could lower the population-level burden of psychotic disorders., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.)
- Published
- 2024
- Full Text
- View/download PDF
83. Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study.
- Author
-
D'Andrea G, Quattrone D, Malone K, Tripoli G, Trotta G, Spinazzola E, Gayer-Anderson C, Jongsma HE, Sideli L, Stilo SA, La Cascia C, Ferraro L, Lasalvia A, Tosato S, Tortelli A, Velthorst E, de Haan L, Llorca PM, Rossi Menezes P, Santos JL, Arrojo M, Bobes J, Sanjuán J, Bernardo M, Arango C, Kirkbride JB, Jones PB, Rutten BP, Van Os J, Selten JP, Vassos E, Schürhoff F, Szöke A, Pignon B, O'Donovan M, Richards A, Morgan C, Di Forti M, Tarricone I, and Murray RM
- Subjects
- Humans, Male, Female, Europe epidemiology, Adult, Brazil epidemiology, Young Adult, Adolescent, Incidence, Middle Aged, Phenotype, Psychotic Disorders epidemiology, Schizotypal Personality Disorder epidemiology
- Abstract
Background: Incidence of first-episode psychosis (FEP) varies substantially across geographic regions. Phenotypes of subclinical psychosis (SP), such as psychotic-like experiences (PLEs) and schizotypy, present several similarities with psychosis. We aimed to examine whether SP measures varied across different sites and whether this variation was comparable with FEP incidence within the same areas. We further examined contribution of environmental and genetic factors to SP., Methods: We used data from 1497 controls recruited in 16 different sites across 6 countries. Factor scores for several psychopathological dimensions of schizotypy and PLEs were obtained using multidimensional item response theory models. Variation of these scores was assessed using multi-level regression analysis to estimate individual and between-sites variance adjusting for age, sex, education, migrant, employment and relational status, childhood adversity, and cannabis use. In the final model we added local FEP incidence as a second-level variable. Association with genetic liability was examined separately., Results: Schizotypy showed a large between-sites variation with up to 15% of variance attributable to site-level characteristics. Adding local FEP incidence to the model considerably reduced the between-sites unexplained schizotypy variance. PLEs did not show as much variation. Overall, SP was associated with younger age, migrant, unmarried, unemployed and less educated individuals, cannabis use, and childhood adversity. Both phenotypes were associated with genetic liability to schizophrenia., Conclusions: Schizotypy showed substantial between-sites variation, being more represented in areas where FEP incidence is higher. This supports the hypothesis that shared contextual factors shape the between-sites variation of psychosis across the spectrum.
- Published
- 2024
- Full Text
- View/download PDF
84. A simulated pedagogical intervention to educate nurse practitioner students about human trafficking.
- Author
-
Valdes B, Salani D, Falcon A, McKay M, Arrojo M, Quintana A, and DeSantis JP
- Subjects
- Humans, United States, Health Personnel education, Educational Status, Students, Human Trafficking prevention & control, Nurse Practitioners education
- Abstract
Abstract: Human trafficking (HT) affects an estimated 40.3 million people globally with 24.9 million people affected in forced labor and 4.8 million in forced sexual exploitation. An estimated 18,000 people are trafficked yearly into the United States. Reports suggest that between 63% and 87% of trafficked persons were seen by health care professionals and were unrecognized while in captivity. The authors designed and implemented an innovative pedagogical intervention for nurse practitioner (NP) students using a 10-min simulation-based education encounter with a standardized patient depicting a potential sex or labor HT clinical presentation. Results demonstrated that simulation-based education is a feasible way to provide HT education to NP students. It is imperative that future NPs receive education/training about HT to recognize potential victims and promote access to appropriate resources., Competing Interests: Competing interests: The authors report no conflicts of interest., (Copyright © 2023 American Association of Nurse Practitioners.)
- Published
- 2023
- Full Text
- View/download PDF
85. The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.
- Author
-
Spinazzola E, Quattrone D, Rodriguez V, Trotta G, Alameda L, Tripoli G, Gayer-Anderson C, Freeman TP, Johnson EC, Jongsma HE, Stilo S, La Cascia C, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Tarricone I, D'Andrea G, Galatolo M, Tortelli A, Tagliabue I, Turco M, Pompili M, Selten JP, de Haan L, Rossi Menezes P, Del Ben CM, Santos JL, Arrojo M, Bobes J, Sanjuán J, Bernardo M, Arango C, Kirkbride JB, Jones PB, O'Donovan M, Rutten BP, Van Os J, Morgan C, Sham PC, Austin-Zimmerman I, Li Z, Vassos E, Murray RM, and Di Forti M
- Subjects
- Humans, Case-Control Studies, Risk Factors, Cannabis adverse effects, Marijuana Smoking adverse effects, Psychotic Disorders epidemiology
- Abstract
Background: While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis., Methods: We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case-control study. 558 first-episode psychosis patients (FEPp) and 567 population controls who had used cannabis and reported their RFUC.We ran logistic regressions to examine whether RFUC were associated with first-episode psychosis (FEP) case-control status. Path analysis then examined the relationship between RFUC, subsequent patterns of cannabis use, and case-control status., Results: Controls (86.1%) and FEPp (75.63%) were most likely to report 'because of friends' as their most common RFUC. However, 20.1% of FEPp compared to 5.8% of controls reported: 'to feel better' as their RFUC (χ
2 = 50.97; p < 0.001). RFUC 'to feel better' was associated with being a FEPp (OR 1.74; 95% CI 1.03-2.95) while RFUC 'with friends' was associated with being a control (OR 0.56; 95% CI 0.37-0.83). The path model indicated an association between RFUC 'to feel better' with heavy cannabis use and with FEPp-control status., Conclusions: Both FEPp and controls usually started using cannabis with their friends, but more patients than controls had begun to use 'to feel better'. People who reported their reason for first using cannabis to 'feel better' were more likely to progress to heavy use and develop a psychotic disorder than those reporting 'because of friends'.- Published
- 2023
- Full Text
- View/download PDF
86. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.
- Author
-
Trotta G, Rodriguez V, Quattrone D, Spinazzola E, Tripoli G, Gayer-Anderson C, Freeman TP, Jongsma HE, Sideli L, Aas M, Stilo SA, La Cascia C, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Tarricone I, D'Andrea G, Tortelli A, Schürhoff F, Szöke A, Pignon B, Selten JP, Velthorst E, de Haan L, Llorca PM, Rossi Menezes P, Del Ben CM, Santos JL, Arrojo M, Bobes J, Sanjuán J, Bernardo M, Arango C, Kirkbride JB, Jones PB, Richards A, Rutten BP, Van Os J, Austin-Zimmerman I, Li Z, Morgan C, Sham PC, Vassos E, Wong C, Bentall R, Fisher HL, Murray RM, Alameda L, and Di Forti M
- Subjects
- Humans, Child, Case-Control Studies, Cannabis adverse effects, Adverse Childhood Experiences, Psychotic Disorders epidemiology, Psychotic Disorders etiology, Psychotic Disorders psychology, Schizophrenia epidemiology, Schizophrenia complications
- Abstract
Background: Childhood adversity and cannabis use are considered independent risk factors for psychosis, but whether different patterns of cannabis use may be acting as mediator between adversity and psychotic disorders has not yet been explored. The aim of this study is to examine whether cannabis use mediates the relationship between childhood adversity and psychosis., Methods: Data were utilised on 881 first-episode psychosis patients and 1231 controls from the European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Detailed history of cannabis use was collected with the Cannabis Experience Questionnaire. The Childhood Experience of Care and Abuse Questionnaire was used to assess exposure to household discord, sexual, physical or emotional abuse and bullying in two periods: early (0-11 years), and late (12-17 years). A path decomposition method was used to analyse whether the association between childhood adversity and psychosis was mediated by (1) lifetime cannabis use, (2) cannabis potency and (3) frequency of use., Results: The association between household discord and psychosis was partially mediated by lifetime use of cannabis (indirect effect coef. 0.078, s.e. 0.022, 17%), its potency (indirect effect coef. 0.059, s.e. 0.018, 14%) and by frequency (indirect effect coef. 0.117, s.e. 0.038, 29%). Similar findings were obtained when analyses were restricted to early exposure to household discord., Conclusions: Harmful patterns of cannabis use mediated the association between specific childhood adversities, like household discord, with later psychosis. Children exposed to particularly challenging environments in their household could benefit from psychosocial interventions aimed at preventing cannabis misuse.
- Published
- 2023
- Full Text
- View/download PDF
87. Tobacco use in first-episode psychosis, a multinational EU-GEI study.
- Author
-
Sánchez-Gutiérrez T, Rodríguez-Toscano E, Roldán L, Ferraro L, Parellada M, Calvo A, López G, Rapado-Castro M, La Barbera D, La Cascia C, Tripoli G, Di Forti M, Murray RM, Quattrone D, Morgan C, van Os J, García-Portilla P, Al-Halabí S, Bobes J, de Haan L, Bernardo M, Santos JL, Sanjuán J, Arrojo M, Ferchiou A, Szoke A, Rutten BP, Stilo S, D'Andrea G, Tarricone I, Díaz-Caneja CM, and Arango C
- Subjects
- Humans, Tobacco Use epidemiology, Psychotic Disorders epidemiology, Psychotic Disorders diagnosis, Schizophrenia epidemiology, Cannabis adverse effects, Substance-Related Disorders
- Abstract
Background: Tobacco is a highly prevalent substance of abuse in patients with psychosis. Previous studies have reported an association between tobacco use and schizophrenia. The aim of this study was to analyze the relationship between tobacco use and first-episode psychosis (FEP), age at onset of psychosis, and specific diagnosis of psychosis., Methods: The sample consisted of 1105 FEP patients and 1355 controls from the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We assessed substance use with the Tobacco and Alcohol Questionnaire and performed a series of regression analyses using case-control status, age of onset of psychosis, and diagnosis as outcomes and tobacco use and frequency of tobacco use as predictors. Analyses were adjusted for sociodemographic characteristics, alcohol, and cannabis use., Results: After controlling for cannabis use, FEP patients were 2.6 times more likely to use tobacco [ p ⩽ 0.001; adjusted odds ratio (AOR) 2.6; 95% confidence interval (CI) [2.1-3.2]] and 1.7 times more likely to smoke 20 or more cigarettes a day ( p = 0.003; AOR 1.7; 95% CI [1.2-2.4]) than controls. Tobacco use was associated with an earlier age at psychosis onset ( β = -2.3; p ⩽ 0.001; 95% CI [-3.7 to -0.9]) and was 1.3 times more frequent in FEP patients with a diagnosis of schizophrenia than in other diagnoses of psychosis (AOR 1.3; 95% CI [1.0-1.8]); however, these results were no longer significant after controlling for cannabis use., Conclusions: Tobacco and heavy-tobacco use are associated with increased odds of FEP. These findings further support the relevance of tobacco prevention in young populations.
- Published
- 2023
- Full Text
- View/download PDF
88. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study.
- Author
-
D'Andrea G, Lal J, Tosato S, Gayer-Anderson C, Jongsma HE, Stilo SA, van der Ven E, Quattrone D, Velthorst E, Berardi D, Rossi Menezes P, Arango C, Parellada M, Lasalvia A, La Cascia C, Ferraro L, La Barbera D, Sideli L, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Tripoli G, Llorca PM, de Haan L, Selten JP, Tortelli A, Szöke A, Muratori R, Rutten BP, van Os J, Jones PB, Kirkbride JB, Murray RM, di Forti M, Tarricone I, and Morgan C
- Subjects
- Child, Humans, Ethnicity, Incidence, Psychotic Disorders epidemiology, Transients and Migrants, Child Abuse
- Abstract
Background: Child maltreatment (CM) and migrant status are independently associated with psychosis. We examined prevalence of CM by migrant status and tested whether migrant status moderated the association between CM and first-episode psychosis (FEP). We further explored whether differences in CM exposure contributed to variations in the incidence rates of FEP by migrant status., Methods: We included FEP patients aged 18-64 years in 14 European sites and recruited controls representative of the local populations. Migrant status was operationalized according to generation (first/further) and region of origin (Western/non-Western countries). The reference population was composed by individuals of host country's ethnicity. CM was assessed with Childhood Trauma Questionnaire. Prevalence ratios of CM were estimated using Poisson regression. We examined the moderation effect of migrant status on the odds of FEP by CM fitting adjusted logistic regressions with interaction terms. Finally, we calculated the population attributable fractions (PAFs) for CM by migrant status., Results: We examined 849 FEP cases and 1142 controls. CM prevalence was higher among migrants, their descendants and migrants of non-Western heritage. Migrant status, classified by generation (likelihood test ratio:χ
2 = 11.3, p = 0.004) or by region of origin (likelihood test ratio:χ2 = 11.4, p = 0.003), attenuated the association between CM and FEP. PAFs for CM were higher among all migrant groups compared with the reference populations., Conclusions: The higher exposure to CM, despite a smaller effect on the odds of FEP, accounted for a greater proportion of incident FEP cases among migrants. Policies aimed at reducing CM should consider the increased vulnerability of specific subpopulations.- Published
- 2023
- Full Text
- View/download PDF
89. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case-control study.
- Author
-
Sideli L, Aas M, Quattrone D, La Barbera D, La Cascia C, Ferraro L, Alameda L, Velthorst E, Trotta G, Tripoli G, Schimmenti A, Fontana A, Gayer-Anderson C, Stilo S, Seminerio F, Sartorio C, Marrazzo G, Lasalvia A, Tosato S, Tarricone I, Berardi D, D'Andrea G, Arango C, Arrojo M, Bernardo M, Bobes J, Sanjuán J, Santos JL, Menezes PR, Del-Ben CM, Jongsma HE, Jones PB, Kirkbride JB, Llorca PM, Tortelli A, Pignon B, de Haan L, Selten JP, Van Os J, Rutten BP, Bentall R, Di Forti M, Murray RM, Morgan C, and Fisher HL
- Subjects
- Adult, Humans, Child, Case-Control Studies, Cognition, Psychotic Disorders genetics, Schizophrenia epidemiology, Schizophrenia genetics, Child Abuse
- Abstract
This study investigated if the association between childhood maltreatment and cognition among psychosis patients and community controls was partially accounted for by genetic liability for psychosis. Patients with first-episode psychosis (N = 755) and unaffected controls (N = 1219) from the EU-GEI study were assessed for childhood maltreatment, intelligence quotient (IQ), family history of psychosis (FH), and polygenic risk score for schizophrenia (SZ-PRS). Controlling for FH and SZ-PRS did not attenuate the association between childhood maltreatment and IQ in cases or controls. Findings suggest that these expressions of genetic liability cannot account for the lower levels of cognition found among adults maltreated in childhood., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
90. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study.
- Author
-
Rodríguez-Toscano E, Alloza C, Fraguas D, Durán-Cutilla M, Roldán L, Sánchez-Gutiérrez T, López-Montoya G, Parellada M, Moreno C, Gayer-Anderson C, Jongsma HE, Di Forti M, Quattrone D, Velthorst E, de Haan L, Selten JP, Szöke A, Llorca PM, Tortelli A, Bobes J, Bernardo M, Sanjuán J, Luis Santos J, Arrojo M, Tarricone I, Berardi D, Ruggeri M, Lasalvia A, Ferraro L, La Cascia C, La Barbera D, Menezes PR, Del-Ben CM, Rutten BP, van Os J, Jones PB, Murray RM, Kirkbride JB, Morgan C, Díaz-Caneja CM, and Arango C
- Subjects
- Humans, Europe, Ethnicity, Incidence, Psychotic Disorders epidemiology, Psychotic Disorders psychology, Cannabis adverse effects, Central Nervous System Stimulants
- Abstract
Background: Use of illegal stimulants is associated with an increased risk of psychotic disorder. However, the impact of stimulant use on odds of first-episode psychosis (FEP) remains unclear. Here, we aimed to describe the patterns of stimulant use and examine their impact on odds of FEP., Methods: We included patients with FEP aged 18-64 years who attended psychiatric services at 17 sites across 5 European countries and Brazil, and recruited controls representative of each local population (FEP = 1130; controls = 1497). Patterns of stimulant use were described. We computed fully adjusted logistic regression models (controlling for age, sex, ethnicity, cannabis use, and education level) to estimate their association with odds of FEP. Assuming causality, we calculated the population-attributable fractions for stimulant use associated with the odds for FEP., Findings: Prevalence of lifetime and recent stimulant use in the FEP sample were 14.50% and 7.88% and in controls 10.80% and 3.8%, respectively. Recent and lifetime stimulant use was associated with increased odds of FEP compared with abstainers [fully adjusted odds ratio 1.74,95% confidence interval (CI) 1.20-2.54, P = .004 and 1.62, 95% CI 1.25-2.09, P < .001, respectively]. According to PAFs, a substantial number of FEP cases (3.35% [95% CI 1.31-4.78] for recent use and 7.61% [95% CI 3.68-10.54] for lifetime use) could have been prevented if stimulants were no longer available and the odds of FEP and PAFs for lifetime and recent stimulant use varied across countries., Interpretation: Illegal stimulant use has a significant and clinically relevant influence on FEP incidence, with varying impacts across countries., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
91. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.
- Author
-
Rodriguez V, Alameda L, Quattrone D, Tripoli G, Gayer-Anderson C, Spinazzola E, Trotta G, Jongsma HE, Stilo S, La Cascia C, Ferraro L, La Barbera D, Lasalvia A, Tosato S, Tarricone I, Bonora E, Jamain S, Selten JP, Velthorst E, de Haan L, Llorca PM, Arrojo M, Bobes J, Bernardo M, Arango C, Kirkbride J, Jones PB, Rutten BP, Richards A, Sham PC, O'Donovan M, Van Os J, Morgan C, Di Forti M, Murray RM, and Vassos E
- Subjects
- Humans, Case-Control Studies, Genetic Predisposition to Disease, Risk Factors, Multifactorial Inheritance, Schizophrenia diagnosis, Schizophrenia genetics, Psychotic Disorders diagnosis, Psychotic Disorders genetics, Psychotic Disorders psychology
- Abstract
Background: Schizophrenia (SZ), bipolar disorder (BD) and depression (D) run in families. This susceptibility is partly due to hundreds or thousands of common genetic variants, each conferring a fractional risk. The cumulative effects of the associated variants can be summarised as a polygenic risk score (PRS). Using data from the EUropean Network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) first episode case-control study, we aimed to test whether PRSs for three major psychiatric disorders (SZ, BD, D) and for intelligent quotient (IQ) as a neurodevelopmental proxy, can discriminate affective psychosis (AP) from schizophrenia-spectrum disorder (SSD)., Methods: Participants (842 cases, 1284 controls) from 16 European EU-GEI sites were successfully genotyped following standard quality control procedures. The sample was stratified based on genomic ancestry and analyses were done only on the subsample representing the European population (573 cases, 1005 controls). Using PRS for SZ, BD, D, and IQ built from the latest available summary statistics, we performed simple or multinomial logistic regression models adjusted for 10 principal components for the different clinical comparisons., Results: In case-control comparisons PRS-SZ, PRS-BD and PRS-D distributed differentially across psychotic subcategories. In case-case comparisons, both PRS-SZ [odds ratio (OR) = 0.7, 95% confidence interval (CI) 0.54-0.92] and PRS-D (OR = 1.31, 95% CI 1.06-1.61) differentiated AP from SSD; and within AP categories, only PRS-SZ differentiated BD from psychotic depression (OR = 2.14, 95% CI 1.23-3.74)., Conclusions: Combining PRS for severe psychiatric disorders in prediction models for psychosis phenotypes can increase discriminative ability and improve our understanding of these phenotypes. Our results point towards the potential usefulness of PRSs in specific populations such as high-risk or early psychosis phases.
- Published
- 2023
- Full Text
- View/download PDF
92. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study.
- Author
-
Fusar-Poli L, Prachason T, Erzin G, Pries LK, Brondino N, Politi P, Delespaul P, Kenis G, Luykx JJ, Lin BD, Richards AL, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Escarti MJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, Arango C, O'Donovan M, van Os J, Rutten BP, and Guloksuz S
- Subjects
- Adult, Humans, Cross-Sectional Studies, Schizophrenia epidemiology, Siblings psychology, Case-Control Studies, Cognition Disorders epidemiology, Male, Female, Cognition, Exposome, Schizophrenic Psychology
- Abstract
Background: People with schizophrenia spectrum disorders (SSD) frequently present cognitive impairments. Here, we investigated whether the exposome score for schizophrenia (ES-SCZ) - a cumulative environmental exposure score - was associated with impairments of neurocognition, social cognition, and perception in patients with SSD, their unaffected siblings, and healthy controls., Methods: This cross-sectional sample consisted of 1200 patients, 1371 siblings, and 1564 healthy controls. Neurocognition, social cognition, and perception were assesed using a short version of the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III), the Degraded Facial Affect Recognition Task (DFAR), and the Benton Facial Recognition Test (BFR), respectively. Regression models were used to analyze the association between ES-SCZ and cognitive domains in each group., Results: There were no statistically significant associations between ES-SCZ and cognitive domains in SSD. ES-SCZ was negatively associated with T-score of cognition in siblings (B=-0.40, 95% CI -0.76 to -0.03) and healthy controls (B=-0.63, 95% CI -1.06 to -0.21). Additionally, ES-SCZ was positively associated with DFAR-total in siblings (B=0.83, 95% CI 0.26 to 1.40). Sensitivity analyses excluding cannabis use history from ES-SCZ largely confirmed the main findings., Conclusions: Longitudinal cohorts may elucidate how environmental exposures influence the onset and course of cognitive impairments in trans-syndromic psychosis spectrum., Competing Interests: Declaration of Competing Interest Celso Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Julio Bobes has received research grants and served as a consultant, advisor, or speaker within the last 5 years for AB-Biotics, Acadia Pharmaceuticals, Alkermes, Allergan, Ambrosetti-Angelini, Biogen, Casen Recordati, D&A Pharma, Exeltis, Gilead, Indivior, GW Pharmaceuticals, Janssen-Cilag, Jazz Pharmaceuticals, Lundbeck, Mundipharma, Newron, Otsuka, Pfizer, Roche, Sage Therapeutics, Servier, Schwabe Farma Ibérica, Shire, and Takeda and has received research funding from the Spanish Ministry of Economy and Competiveness –Centro de Investigación Biomedica en Red area de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III– and the Spanish Ministry of Health. Maria Paz García-Portilla has been a consultant to and/or has received honoraria/grants from Angelini, Otsuka-Lundbeck Alliance, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, and Sage Therapeutics. Pilar A. Sáiz has been a consultant to and/or has received honoraria/research grants from Adamed, Alter Medica, Angelini Pharma, CIBERSAM, Ethypharm Digital Therapy, European Commission, Government of the Principality of Asturias, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Plan Nacional Sobre Drogas, and Servier. Miguel Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
93. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis-findings from the EU-GEI study.
- Author
-
Alameda L, Liu Z, Sham PC, Aas M, Trotta G, Rodriguez V, Di Forti M, Stilo SA, Kandaswamy R, Arango C, Arrojo M, Bernardo M, Bobes J, de Haan L, Del-Ben CM, Gayer-Anderson C, Sideli L, Jones PB, Jongsma HE, Kirkbride JB, La Cascia C, Lasalvia A, Tosato S, Llorca PM, Menezes PR, van Os J, Quattrone D, Rutten BP, Santos JL, Sanjuán J, Selten JP, Szöke A, Tarricone I, Tortelli A, Velthorst E, Morgan C, Dempster E, Hannon E, Burrage J, Dwir D, Arumuham A, Mill J, Murray RM, and Wong CCY
- Subjects
- Humans, Child, DNA Methylation genetics, Epigenome, Adverse Childhood Experiences, Psychotic Disorders genetics, Psychological Tests, Self Report
- Abstract
Abtract: Studies conducted in psychotic disorders have shown that DNA-methylation (DNAm) is sensitive to the impact of Childhood Adversity (CA). However, whether it mediates the association between CA and psychosis is yet to be explored. Epigenome wide association studies (EWAS) using the Illumina Infinium-Methylation EPIC array in peripheral blood tissue from 366 First-episode of psychosis and 517 healthy controls was performed. Adversity scores were created for abuse, neglect and composite adversity with the Childhood Trauma Questionnaire (CTQ). Regressions examining (I) CTQ scores with psychosis; (II) with DNAm EWAS level and (III) between DNAm and caseness, adjusted for a variety of confounders were conducted. Divide-Aggregate Composite-null Test for the composite null-hypothesis of no mediation effect was conducted. Enrichment analyses were conducted with missMethyl package and the KEGG database. Our results show that CA was associated with psychosis (Composite: OR = 1.68; p = <0.001; abuse: OR = 2.16; p < 0.001; neglect: OR = 2.27; p = <0.001). None of the CpG sites significantly mediated the adversity-psychosis association after Bonferroni correction (p < 8.1 × 10
-8 ). However, 28, 34 and 29 differentially methylated probes associated with 21, 27, 20 genes passed a less stringent discovery threshold (p < 5 × 10-5 ) for composite, abuse and neglect respectively, with a lack of overlap between abuse and neglect. These included genes previously associated to psychosis in EWAS studies, such as PANK1, SPEG TBKBP1, TSNARE1 or H2R. Downstream gene ontology analyses did not reveal any biological pathways that survived false discovery rate correction. Although at a non-significant level, DNAm changes in genes previously associated with schizophrenia in EWAS studies may mediate the CA-psychosis association. These results and associated involved processes such as mitochondrial or histaminergic disfunction, immunity or neural signalling requires replication in well powered samples. The lack of overlap between mediating genes associated with abuse and neglect suggests differential biological trajectories linking CA subtypes and psychosis., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2023
- Full Text
- View/download PDF
94. Epidemiological characteristics and hospitalization trajectories prior to suicide in Galicia between 2013 and 2016.
- Author
-
Blanco V, Tajes Alonso M, Peleteiro Pensado LF, Naveira Barbeito G, Núñez Arias D, Torres ÁJ, Arrojo M, Páramo M, Otero P, and Vázquez FL
- Subjects
- Male, Humans, Middle Aged, Hospitalization, Research Design, Suicide psychology, Mental Disorders epidemiology
- Abstract
Introduction: Addressing suicide requires an understanding of regional patterns of epidemiology, with health variables being central. However, the clinical profile of people who commit suicide has received little attention. The objectives of this study were to analyze the sociodemographic, clinical, and forensic characteristics of persons who committed suicide in Galicia between 2013 and 2016, analyze suicide mortality rates, and identify trajectories of hospitalizations and associated variables., Material and Methods: A population study was carried out on the 1354 people who died by suicide in Galicia., Results: The most common profile was a retired man, 57.9 years old (SD=18.5), from an urban and inner area. 43.6% had been previously hospitalized, 41.6% had been diagnosed with physical disorders, and 26.8% with mental disorders. 48.2% had been prescribed psychiatric medications and 29.6% had received outpatient psychiatric care. The highest prevalence of death by suicide (27.5%) was in 2014, with the predominant method being hanging (59.1%). The average raw rate was 12.3/100,000. Three trajectories of hospitalizations emerged: 94.83% had experienced few hospitalizations; 2.95% an increasing pattern; and 2.22% a decreasing pattern. These trajectories were associated with number of psychiatric appointments, prescription of psychiatric medications, and diagnoses of physical and mental disorders., Conclusions: These findings are crucial for detection and prevention., (Copyright © 2021 Sociedad Española de Psiquiatría y Salud Mental (SEPSM). Published by Elsevier España S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
95. Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study.
- Author
-
Aas M, Alameda L, Di Forti M, Quattrone D, Dazzan P, Trotta A, Ferraro L, Rodriguez V, Vassos E, Sham P, Tripoli G, Cascia C, Barbera D, Tarricone I, Muratori R, Berardi D, Lasalvia A, Tosato S, Szöke A, Llorca PM, Arango C, Tortelli A, de Haan L, Velthorst E, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Menezes PR, Selten JP, Jones PB, Jongsma HE, Kirkbride JB, Rutten BPF, van Os J, Gayer-Anderson C, Murray RM, and Morgan C
- Subjects
- Humans, Genomics, Multifactorial Inheritance, Odds Ratio, Adverse Childhood Experiences, Psychotic Disorders etiology, Psychotic Disorders genetics
- Abstract
Background: A history of childhood adversity is associated with psychotic disorder, with an increase in risk according to the number of exposures. However, it is not known why only some exposed individuals go on to develop psychosis. One possibility is pre-existing polygenic vulnerability. Here, we investigated, in the largest sample of first-episode psychosis (FEP) cases to date, whether childhood adversity and high polygenic risk scores for schizophrenia (SZ-PRS) combine synergistically to increase the risk of psychosis, over and above the effect of each alone., Methods: We assigned a schizophrenia-polygenic risk score (SZ-PRS), calculated from the Psychiatric Genomics Consortium (PGC2), to all participants in a sample of 384 FEP patients and 690 controls from the case-control component of the EU-GEI study. Only participants of European ancestry were included in the study. A history of childhood adversity was collected using the Childhood Trauma Questionnaire (CTQ). Synergistic effects were estimated using the interaction contrast ratio (ICR) [odds ratio (OR)
exposure and PRS - ORexposure - ORPRS + 1] with adjustment for potential confounders., Results: There was some evidence that the combined effect of childhood adversities and polygenic risk was greater than the sum of each alone, as indicated by an ICR greater than zero [i.e. ICR 1.28, 95% confidence interval (CI) -1.29 to 3.85]. Examining subtypes of childhood adversities, the strongest synergetic effect was observed for physical abuse (ICR 6.25, 95% CI -6.25 to 20.88)., Conclusions: Our findings suggest possible synergistic effects of genetic liability and childhood adversity experiences in the onset of FEP, but larger samples are needed to increase precision of estimates.- Published
- 2023
- Full Text
- View/download PDF
96. Authors' response: Highly pathogenic influenza A(H5N1) viruses in farmed mink outbreak contain a disrupted second sialic acid binding site in neuraminidase, similar to human influenza A viruses.
- Author
-
Agüero M, Monne I, Sánchez A, Zecchin B, Fusaro A, Ruano MJ, Del Valle Arrojo M, Fernández-Antonio R, Souto AM, Tordable P, Cañás J, Bonfante F, Giussani E, Terregino C, and Orejas JJ
- Subjects
- Animals, Binding Sites, Disease Outbreaks veterinary, Hemagglutinin Glycoproteins, Influenza Virus, Mink virology, N-Acetylneuraminic Acid, Neuraminidase genetics, Influenza A virus, Influenza A Virus, H5N1 Subtype genetics, Orthomyxoviridae Infections epidemiology, Orthomyxoviridae Infections veterinary
- Published
- 2023
- Full Text
- View/download PDF
97. Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022.
- Author
-
Agüero M, Monne I, Sánchez A, Zecchin B, Fusaro A, Ruano MJ, Del Valle Arrojo M, Fernández-Antonio R, Souto AM, Tordable P, Cañás J, Bonfante F, Giussani E, Terregino C, and Orejas JJ
- Subjects
- Humans, Animals, Mink, Spain epidemiology, Farms, Phylogeny, Influenza in Birds epidemiology, Influenza A Virus, H5N1 Subtype genetics, Influenza A virus, Influenza, Human epidemiology
- Abstract
In October 2022, an outbreak in Europe of highly pathogenic avian influenza (HPAI) A(H5N1) in intensively farmed minks occurred in northwest Spain. A single mink farm hosting more than 50,000 minks was involved. The identified viruses belong to clade 2.3.4.4b, which is responsible of the ongoing epizootic in Europe. An uncommon mutation (T271A) in the PB2 gene with potential public health implications was found. Our investigations indicate onward mink transmission of the virus may have occurred in the affected farm.
- Published
- 2023
- Full Text
- View/download PDF
98. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study.
- Author
-
Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, Aguglia E, Arango C, Rutten BP, and Guloksuz S
- Subjects
- Cannabinoid Receptor Agonists, Cross-Sectional Studies, Emotions, Humans, Siblings psychology, Cannabis, Facial Recognition, Psychotic Disorders psychology, Schizophrenia complications
- Abstract
Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples., Competing Interests: Conflicts of Interest Celso Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Maria Paz Garcia-Portilla has been a consultant to and/or has received honoraria/grants from Angelini, Alianza Otsuka-Lundbeck, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, and SAGE Therapeutics., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
99. Migration history and risk of psychosis: results from the multinational EU-GEI study.
- Author
-
Tarricone I, D'Andrea G, Jongsma HE, Tosato S, Gayer-Anderson C, Stilo SA, Suprani F, Iyegbe C, van der Ven E, Quattrone D, di Forti M, Velthorst E, Rossi Menezes P, Arango C, Parellada M, Lasalvia A, La Cascia C, Ferraro L, Bobes J, Bernardo M, Sanjuán I, Santos JL, Arrojo M, Del-Ben CM, Tripoli G, Llorca PM, de Haan L, Selten JP, Tortelli A, Szöke A, Muratori R, Rutten BP, van Os J, Jones PB, Kirkbride JB, Berardi D, Murray RM, and Morgan C
- Subjects
- Humans, Case-Control Studies, Ethnicity, Psychotic Disorders epidemiology, Schizophrenia epidemiology, Schizophrenia etiology, Transients and Migrants
- Abstract
Background: Psychosis rates are higher among some migrant groups. We hypothesized that psychosis in migrants is associated with cumulative social disadvantage during different phases of migration., Methods: We used data from the EUropean Network of National Schizophrenia Networks studying Gene-Environment Interactions (EU-GEI) case-control study. We defined a set of three indicators of social disadvantage for each phase: pre-migration, migration and post-migration. We examined whether social disadvantage in the pre- and post-migration phases, migration adversities, and mismatch between achievements and expectations differed between first-generation migrants with first-episode psychosis and healthy first-generation migrants, and tested whether this accounted for differences in odds of psychosis in multivariable logistic regression models., Results: In total, 249 cases and 219 controls were assessed. Pre-migration (OR 1.61, 95% CI 1.06-2.44, p = 0.027) and post-migration social disadvantages (OR 1.89, 95% CI 1.02-3.51, p = 0.044), along with expectations/achievements mismatch (OR 1.14, 95% CI 1.03-1.26, p = 0.014) were all significantly associated with psychosis. Migration adversities (OR 1.18, 95% CI 0.672-2.06, p = 0.568) were not significantly related to the outcome. Finally, we found a dose-response effect between the number of adversities across all phases and odds of psychosis (⩾6: OR 14.09, 95% CI 2.06-96.47, p = 0.007)., Conclusions: The cumulative effect of social disadvantages before, during and after migration was associated with increased odds of psychosis in migrants, independently of ethnicity or length of stay in the country of arrival. Public health initiatives that address the social disadvantages that many migrants face during the whole migration process and post-migration psychological support may reduce the excess of psychosis in migrants.
- Published
- 2022
- Full Text
- View/download PDF
100. Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study.
- Author
-
Tripoli G, Quattrone D, Ferraro L, Gayer-Anderson C, La Cascia C, La Barbera D, Sartorio C, Seminerio F, Rodriguez V, Tarricone I, Berardi D, Jamain S, Arango C, Tortelli A, Llorca PM, de Haan L, Velthorst E, Bobes J, Bernardo M, Sanjuán J, Luis Santos J, Arrojo M, Marta Del-Ben C, Rossi Menezes P, van der Ven E, Jones PB, Jongsma HE, Kirkbride JB, Tosato S, Lasalvia A, Richards A, O'Donovan M, Rutten BPF, van Os J, Morgan C, Sham PC, Di Forti M, Murray RM, and Murray GK
- Subjects
- Case-Control Studies, Emotions, Facial Expression, Humans, Psychiatric Status Rating Scales, Depressive Disorder, Major complications, Depressive Disorder, Major genetics, Facial Recognition, Psychotic Disorders complications, Schizophrenia complications, Schizophrenia genetics
- Abstract
Background and Hypothesis: Facial Emotion Recognition is a key domain of social cognition associated with psychotic disorders as a candidate intermediate phenotype. In this study, we set out to investigate global and specific facial emotion recognition deficits in first-episode psychosis, and whether polygenic liability to psychotic disorders is associated with facial emotion recognition., Study Design: 828 First Episode Psychosis (FEP) patients and 1308 population-based controls completed assessments of the Degraded Facial Affect Recognition Task (DFAR) and a subsample of 524 FEP and 899 controls provided blood or saliva samples from which we extracted DNA, performed genotyping and computed polygenic risk scores for schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MD)., Study Results: A worse ability to globally recognize facial emotion expressions was found in patients compared with controls [B= -1.5 (0.6), 95% CI -2.7 to -0.3], with evidence for stronger effects on negative emotions (fear [B = -3.3 (1.1), 95% CI -5.3 to -1.2] and anger [B = -2.3 (1.1), 95% CI -4.6 to -0.1]) than on happiness [B = 0.3 (0.7), 95% CI -1 to 1.7]. Pooling all participants, and controlling for confounds including case/control status, facial anger recognition was associated significantly with Schizophrenia Polygenic Risk Score (SZ PRS) [B = -3.5 (1.7), 95% CI -6.9 to -0.2]., Conclusions: Psychosis is associated with impaired recognition of fear and anger, and higher SZ PRS is associated with worse facial anger recognition. Our findings provide evidence that facial emotion recognition of anger might play a role as an intermediate phenotype for psychosis., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.